

Cumulative Index 1989

Volume 73

<i>January</i>	OBESITY , pages 1-269
<i>March</i>	CARDIOVASCULAR PHARMACOTHERAPY III , pages 271-516
<i>May</i>	MEDICAL PROBLEMS IN PREGNANCY , pages 517-752
<i>July</i>	HEPATIC DISEASES , pages 753-1053
<i>September</i>	COLLAGEN VASCULAR DISEASES , pages 1055-1305
<i>November</i>	GERIATRIC MEDICINE , pages 1307-1598

Note: Page numbers of article and issue titles are in **boldface** type.

- Abdomen, acute, in elderly, **1413-1422**. See also *Acute abdomen*.
- Abdominal fat, genetics and, 73-75
- Abdominal-gluteal ratio, 163
for body fat determination, 7
- Abdominal pain, in familial type V hyperlipoproteinemia, 873
- Abortion, definition of, 517
in AIDS patient, 706
induced, and coagulopathy, 736-737
- Abruptio placentae, and disseminated intravascular coagulation, 730-732
- Accelerated aging theory, of Alzheimer's disease, 1386
- Accutane, teratogenic effects of, 576
- Acetaminophen, metabolism of, and liver disease, 786
- Acetazolamide, and metabolic acidosis generation, 279
- Acetic acid, cutaneous reactions to, 1278-1279
- Acid-base abnormalities, in fulminant hepatic failure, 961
- Acne, with corticosteroids, 1284
- Acrodermatitis chronica atrophicans, localized scleroderma vs, 1152-1153
- Actin, in cardiac muscle tension, 286
- Action tremor, in elderly, 1308
- Activity, in management of juvenile dermatomyositis, 1204
- Acute abdomen, in elderly, **1413-1422**
causes of, 1417
differential diagnosis of, 1416-1420
emergency operations for, 1418
initial evaluation of, 1413-1416
mortality in, 1418
outcome of, 1420-1421
sepsis in, inaccurate diagnosis of, 1419
- Acute confusional state, clinical description of, 1399
- Acyclovir, for chronic hepatitis B, 976
- Adaptive devices, role in falls, 1328
- Adipocytes, composition of, 84-89
differentiation of, 91
lipid mobilization from, 84
nutritional regulation of, 90
precursors of, 91
triglyceride uptake by, 84
- Adipose tissue, anatomic characteristics of, 161-162
androgenic activity and, 128-129
cellularity of, 89-93
fatty acid composition of, 84
growth potential of, 128
metabolism of, 87
- Adiposity, obesity vs, 117
regional, metabolic risk factors in, 127-131
- Adrenal function, in obesity, 146-147, 170

- Adrenal steroids, and nutrient balance control, 39
fetal exposure to, 677
- Adrenergic agents, for asthma in pregnancy, 658
- Adrenergic blockers, effect on serum lipids, 465
- Afferent signals, of nutrient balance, 34-36
- Aflatoxins, and hepatocellular carcinoma, 1005
- Afterload, in muscle contraction, 286
- Aging. See also *Elderly*.
and lipoprotein metabolism, 1525-1526
and sexual function, 1483-1495
bone loss with, 1455
factors in, 1531
male hormonal changes with, 1484-1485
nutrition and, 1531-1549
- Agitation, in dementia, treatment of, 1404
- Agnosia, in primary degenerative dementia of the Alzheimer's type, 1396
- Agraphesthesia, with cerebral infarction, 1362
- AIDS, and abortion, 706
breastfeeding in, 593
dementia in, 1398
fetal syndrome of, 704
in women, transmission and distribution of, 702
risk factors for, 701
- Air-fluidized beds, for pressure ulcer treatment, 1518
- Air mattresses, for pressure ulcer treatment, 1517
- Albumin, in liver failure, 943
laboratory standards for, 1541
measurement of, in elderly, 1539
- Alcohol use, amnestic disorder with, 1399
and drug metabolism, 786
and impotence, 1487
role in falls, 1329
teratogenic effects of, 570-571
- Alcoholic liver disease, 815-830. See also under *Liver disease*.
- Alkalosis, in hepatic encephalopathy, 796
- Alopecia, in discoid lupus erythematosus, 1056, 1058
in systemic lupus erythematosus, 1104
- Alpha-adrenergic agents, for stress incontinence, 1435
- Alpha-adrenergic blockers, for Raynaud's phenomenon, 1137
- Alpha-antitrypsin deficiency, and hepatocellular carcinoma, 1002-1003
liver transplantation for, 1017
- Alpha-blockers, effect on plasma lipids, 462
effect on serum lipids, 464
- Alpha-fetoprotein, in hepatocellular carcinoma, 992-993
maternal, in diabetes, 691-692
in fetal diagnosis, 530
- Alstrom-Hallgren syndrome, and obesity, 166
- Alzheimer's disease, and urinary incontinence, 1424
diagnosis of, criteria for, 1397
theories of, 1384-1386
- Amebiasis, and liver abscess, 853
- Amino acids, branched-chain, for hepatic encephalopathy, 805-806
for alcoholic liver disease, 825
- Aminophylline, for acute asthma in pregnancy, 656
- Aminopterin, teratogenic effects of, 573-574
- Ammonia, in hepatic encephalopathy, 800-801
- Amnestic syndromes, clinical description of, 1399-1400
diagnostic criteria for, 1395
- Amniocentesis, in fetal diagnosis, 531-532
in maternal diabetes, 693
- Amniotic fluid embolus, and disseminated intravascular coagulation, 735-736
- Ampicillin, for urinary tract infections, 1445
- Amrinone, chemical structure of, 304
for congestive heart failure, 303-304
hemodynamic response to, 305
- Analgesics, and liver disease, 778, 787
- Androgens, and hepatocellular carcinoma, 1004
- Anemia, and secondary hemochromatosis, 838
in acute abdomen, 1415
in protein-calorie malnutrition, 1543
in pyogenic liver abscess, 849
- Anencephaly, with maternal diabetes, 691
- Anesthetics, and liver disease, 778, 787
- Angina pectoris, myocardial infarction prevention in, 410-411
- Angioplasty, recombinant tissue-type plasminogen activator therapy vs, 398
- Angiotensin, maternal vascular sensitivity to, 543
- Angiotensin-converting enzyme(s), effect on serum lipids, 466
- Angiotensin-converting enzyme inhibitors, adverse effects of, 330-332
clinical efficacy of, 326-328
effect on electrolytes, 323-325
effect on mortality, 329-330
for hypertension, in elderly, 1477
in pregnancy, 634, 672-674
for hyponatremia, 280
hemodynamic effects of, 320-322
humoral effect of, 320
in heart failure, 315-338
renal effects of, 323-325
spectrum of response to, 322
- Animals, obesity in, 23
- Ankylosis, digital, in systemic scleroderma, 1170

- Anomia, in primary degenerative dementia of the Alzheimer's type, 1396
- Anorexia, in pyogenic liver abscess, 849
- Anorexiants, effectiveness of, 241-242 for obesity, 237-240
- Anthranilic acids, cutaneous reactions to, 1281-1282
- Anthropometrics, of elderly, in nutritional assessment, 1537-1539
- Antiarrhythmic drugs, and liver disease, 787
- Antibiotics, contraindicated in newborns, 592 for acute asthma in pregnancy, 657 for hepatic encephalopathy, 806 for pressure ulcer treatment, 1519-1520
- Anticardiolipin antibody, in systemic lupus erythematosus, effect on pregnancy, 611 screening for, 615
- Anticholinergics, for urge incontinence, 1435
- Anticoagulants, circulating, and coagulopathy, 738 for cardiogenic embolism, 1365 in pregnancy, 647-648 teratogenic effects of, 571-572
- Anticonvulsants, and liver disease, 778, 787 half-lives of, 598 in pregnancy, 662-664 teratogenic effects of, 572-573
- Antidepressants, in orthostatic hypotension, 1345 role in falls, 1330
- Antifibrotic agents, for alcoholic liver disease, 825
- Antigout agents, and liver disease, 778
- Antihistamines, for cutaneous drug reactions, 1294 for leukocytoclastic vasculitis, 1232
- Antihypertensive therapy, drugs for, and impotence, 1487 in breast milk, 600 in elderly, benefits of, 1474
- Anti-inflammatory drugs, and liver disease, 778, 787-788 for systemic scleroderma, 1175
- Antilymphocyte globulin, for immunosuppression, in liver transplantation, 1026
- Antimalarials, cutaneous reactions to, 1284-1285 fetal effects of, 613 for cutaneous lupus erythematosus, 1068, 1085 for lupus erythematosus panniculitis, 1124
- Antimicrobials, and liver disease, 778, 787
- Antineoplastics, and liver disease, 779, 788 teratogenic effects of, 573-574
- Antinuclear antibodies, in localized scleroderma, 1149 in lupus erythematosus panniculitis, 1123 in systemic scleroderma, 1173, 1174
- AntiParkinsonism drugs, in orthostatic hypotension, 1345
- Antipressure devices, for pressure ulcer treatment, 1517-1519
- Antipsychotic drugs, in orthostatic hypotension, 1344-1345
- Antispasmodics, and liver disease, 778 for constipation, 1504-1505 for urge incontinence, 1435
- Antithrombin, function of, in coagulation, 725
- Antithymocyte globulin, for immunosuppression, in liver transplantation, 1026-1027
- Antithyroid drugs, teratogenic effects of, 574-575
- Anti-ulcer drugs, and liver disease, 788
- Anxiety, in obesity, 49 in pregnancy, case history of, 552-553
- Aortic aneurysm, ruptured, in elderly, emergency operation for, 1418
- Aortic insufficiency, in pregnancy, 642
- Aortic stenosis, in pregnancy, 642
- Aphasia, in cerebral infarction, 1362 in primary degenerative dementia of the Alzheimer's type, 1396
- Aphthous ulcers, in Behçet's disease, 1240
- ApoC-II, deficiency of, familial, 866-869
- Apolipoproteins, 862
- Apoptosis, 859-860 electrophoresis of, 875
- Appendicitis, in elderly, acute abdomen with, 1416-1418 in pregnancy, case history of, 553
- Appetite suppressants, 239-241
- Apraxia, in cerebral infarction, 1362 in primary degenerative dementia of the Alzheimer's type, 1396
- Aprotinin, for disseminated intravascular coagulation, with abruptio placentae, 732
- Arrhythmias, beta-blockers for, 413-415 cardiac, in pregnancy, 646-647 role in falls, 1330 effect of cocaine on, 479 in fulminant hepatic failure, 960 in hemochromatosis, 837
- Arterial alterations, in pregnancy, surgical implications of, 550
- Arterial blood gases, in acute asthma, 655
- Arterial compliance, and orthostatic hypotension, 1341
- Arthralgias, with cutaneous vasculitis, 1225 with dermatomyositis, 1186 with scleroderma, 1147, 1172
- Arthritis, acute, in elderly, 1375-1376 rheumatoid. See *Rheumatoid arthritis*. with Behçet's disease, 1241 with cutaneous vasculitis, 1225 with dermatomyositis, 1186 with pyoderma gangrenosum, 1253-1254

- Arthropathies, crystal-induced, in elderly, 1372-1373
 in hemochromatosis, 837
- Arthus reaction, in vasculitis, 1223
- Ascites, in hepatic encephalopathy, 796
 in liver failure, 943
- Ascorbic acid, deficiency of, and pressure ulcers, 1513
 for hemochromatosis, 840
- Asphyxia, fetal sensitivity to, 525
 neonatal, 526
- Aspirin, cutaneous reactions to, 1277-1278
 for stroke prophylaxis, 1363
- Asthma, in pregnancy, 653-660
 acute, clinical findings in, 654-655
 treatment of, 656-658
 continuing treatment of, 658-659
 factors provoking, 653
- Ataxia, with cerebellar tremor, 1315
- Atenolol, effect on serum lipids, 458
 for hypertension in pregnancy, 672-674
 in breast milk, 600
- Atheromatous disease, and stroke, 1355
- Atherosclerosis, accelerated, in familial hypercholesterolemia, 869
 prevention of, 879-882
- ATP, in muscle contraction, 288-289
- Atrial fibrillation, and stroke, 1354
- Atrial natriuretic factor, diuresis with, 281
- Atrial septal defect, in pregnancy, 644
- Atrophic vaginitis, and urinary incontinence, 1427
- Attention, testing of, in acquired cognitive disorder, 1390
- Attitude techniques, in weight control program, 193
- Auranofin, cutaneous reactions to, 1286
- Autoantibodies, production of, in chronic cutaneous lupus erythematosus, 1067
- Autoimmune disorders, and Behçet's disease, 1240
 in pregnancy, 605-621
 poor outcome in, markers for, 609-611
 with primary biliary cirrhosis, 913, 915-916
- Autonomic nervous system, and nutrient balance control, 38
 in orthostatic hypotension, 1341, 1343
- Aversion, in weight control, 253
- Azathioprine, and risk of malignancy, 675
 cutaneous reactions to, 1291-1292
 fetal exposure to, effects of, 612, 677-678
 for immunosuppression, in liver transplantation, 1026
 for primary biliary cirrhosis, 921
- Azidothymidine, and liver disease, 788
- Azygos blood flow, measurement of, 937-939
- Bacteremia, with urinary tract catheterization, 1448
- Bacterial endocarditis, prophylaxis for, at delivery, 648
- Bacteriuria, with urinary tract catheterization, 1443-1445
- Balance, in elderly, effect on falling, 1325, 1332
- Balloon tamponade, for esophageal varices, 944
- Bardet-Biedl syndrome, and obesity, 166
- Basal energy expenditure, in elderly, 1541-1542
- Baseline characteristics, in drug trials, failure to control for, 503-504
- Bed elevation, for orthostatic hypotension, 1345
 for pressure ulcer prevention, 1516
- Bedrest, avoidance of, for orthostatic hypotension, 1345
- Behavioral programs, for obesity, 60, 185-201
 cognitive change in, 194
 components of, 190
 conceptual model of, 189
 developmental history of, 185-186
 exercise in, 193
 low calorie diet with, 196
 nutrition in, 193
 pharmacotherapy with, 197
 reinforcement in, 193
 results of, 186-189
 self-monitoring in, 190
 social support in, 193
 stimulus control in, 190
 surgery with, 197
- Behavioral therapy, for urge incontinence, 1435
- Behçet's disease, diagnosis of, 1239-1242
- Benzocaine, for weight control, 245
- Benzodiazepines, receptors for, in hepatic encephalopathy, 802-804
 role in falls, 1330
- Beta-adrenergic blockers. *See Beta-blockers.*
- Beta-adrenergic receptors, catecholamine-induced down-regulation of, beta-blockers for, 376
- Beta-agonists, for acute asthma in pregnancy, 656
 for Raynaud's phenomenon, 1137
 for weight control, 245
- Beta-blockers, benefit of, mechanisms of, 413-416
 clinical trials of, 411-414, 416-418
 clinical use of, 418-421
 contraindications to, 418
 effect on serum lipids, 460
 for heart failure, 373-385

- clinical experience with, 377-380
- evidence against, 379-380
- rationale for avoiding, 373-374
- rationale for using, 374-376
- recommendations for, 381-383
- for hypertension, in elderly, 1476-1477
- in pregnancy, 672-674
- for myocardial infarction, 409-436
 - early phase, 416
 - recommendations for, 431
 - in breast milk, 600-601
- infarct reduction with, randomized trials of, 417
- long-term trials of, results of, 413-414
- pharmacologic properties of, 412
- plasma lipid changes with, 453-461
- with intrinsic sympathomimetic activity, effect on serum lipids, 459
- Beta-endorphin, in obesity, 148
- Bile, constituents of, metabolic relationships among, 755
- Bile acid(s), elevated concentrations of, in primary biliary cirrhosis, 913
- Bile acid binding resins, for hyperlipidemia, 1525
 - lovastatin with, 443
- Bile duct(s), cholangiograms of, 902
- dilated, imaging of, 901
- endoscopic sphincterotomy of, 903
- Bile salt, synthesis of, 756
- Biliary cirrhosis, primary, 911-929
 - and hepatocellular carcinoma, 1001-1002
 - clinical features of, 911-912
 - course of, 918-919
 - demographic characteristics of, 911
 - diagnosis of, 917-918
 - diseases associated with, 912-913
 - epidemiology of, 911
 - liver pathology in, 914
 - liver transplantation for, 1013-1014
 - manifestations of, 911-914
 - pathogenesis of, 915-917
 - prognosis in, 919
 - serologic findings in, 913
 - treatment of, 919-922
- Biliary tract, diseases of, imaging of, 899-901
 - in elderly, acute abdomen with, 1416-1418
- drainage of, for gallstones, 761
- obstruction of, and pyogenic liver abscess, 848
- stents in, 905-905
- Biliointestinal bypass, for weight control, 255
- Biliopancreatic diversion, for weight control, 256
- Bilirubin, in liver failure, 943
- Binswanger's disease, dementia in, 1398
- Bioelectrical impedance, for body fat determination, 7
- Biophysical profile, of fetal status, 537-538
- Bipyridines, effects of, 305
- Birth weight, and perinatal outcome, 524
- Bisacodyl, cathartic dosage of, 1504
- Bladder. See also under *Urinary*.
 - cancer of, with chronic urinary tract catheterization, 1448-1449
 - disorders of, long-term catheterization for, 1441-1442
 - dynamics of, in urinary incontinence, 1425
 - function of, changes with aging, 1426
 - perforation of, with urinary tract catheterization, 1449
- Blood, hypercoagulability of, in pregnancy, 724
- Blood flow, evaluation of, in Raynaud's phenomenon, 1134
- in pregnancy, 640
- Blood pressure, and cardiovascular disease
 - risk factors, 218
 - changes in, role in falling, 1327
 - with standing, 1337-1339
 - effect of cocaine on, 479
 - orthostatic changes in, 1339-1340
- Blood transfusions, and secondary hemochromatosis, 838-839
- Blood viscosity, in Raynaud's phenomenon, 1129
 - inhibitors of, for Raynaud's phenomenon, 1138-1139
- Blood volume, increased, in pregnancy, 543
- Body composition, effect of caloric restriction on, 231-233
- effect of exercise on, 227-233
- Body fat, determination of, 1-7
- distribution of, 1-7
 - and endocrine disorders, 130-131
 - and health risks, 119-131
 - factors influencing, 127-131
 - in obesity, 118-120
 - relationship to metabolic profile, 121
 - genetics and, 71-73
- Body mass-energy expenditure relationship, clinical applications of, 24-25
- Body mass index, 4
 - and risk of obesity, 180
 - for measurement of overweight, 175
 - genetic effect on, 72
 - nomogram for, 176
- Body weight, defense of, 206, 238
- effect of chronic exercise on, 227-233
- lean vs obese, 220-222
- physiological regulation of, and obesity, 15-27
- set-point of, energy expenditure and, 19

- Bone, loss of, effect of calcium on, 1461
mineral density of, and fracture risk, 1458
- Bone disease, metabolic, in primary biliary cirrhosis, 919-920
- Bone marrow transplant patient, pregnancy in, 681
- Bowel bypass syndrome, with Sweet's syndrome, 1238
- Bowel resection, for pyoderma gangrenosum, 1257
- Bowel retraining, in constipation treatment, 1503
- Brain scan, in acquired cognitive disorder, 1393
- Breast(s), development of, 584-585
plugged duct in, differential diagnosis of, 596
- Breast cancer, in obesity, 114
with primary biliary cirrhosis, 912
- Breastfeeding, and medical disease, 583-603
by AIDS patient, 593, 707
by renal transplant patients, 681
drugs in, 588-589
in chicken pox, 594
in diabetes mellitus, 594-597, 695
in epilepsy, 598-599
in heart disease, 599-601
in hepatitis, 593
in herpes simplex, 593-594
in hypertension, 599-601
in infectious disease, 591-594
in mastitis, 592
in noninfectious diseases, 594-601
in thyroid disease, 594-597
in toxic shock syndrome, 592
in tuberculosis, 592
reasons for, 583-584
- Breast milk, human immunodeficiency virus in, 705
- Breast pumping, of contaminated milk, 590
- Brown fat, function of, 99
- Bruising, in hepatic encephalopathy, 796
- Budd-Chiari syndrome, drug-induced, 782
liver transplantation for, 1018-1019
- Bulk agents, cathartic dosage of, 1504
- Butterfly rash, in acute cutaneous lupus erythematosus, 1094-1095
- Calcification, in lupus erythematosus panniculitis, 1119, 1121
- Calcinosis, digital, in systemic scleroderma, 1169
in dermatomyositis, 1212
in juvenile dermatomyositis, 1196, 1198
management of, 1205-1206
- Calcitonin, for osteoporosis, 1467
- Calcium, and muscle contraction regulation, 288-290
- binding of, anticoagulant interference with, 571
for osteoporosis, 1460-1462
- Calcium antagonists, and heart failure, 339-359
comparison of, 351
effects on cardiac performance, 340
for heart failure, recommendations for, 353
mechanisms of action of, 339-343
- Calcium channel blockers, effect on serum lipids, 466
for hypertension, in elderly, 1477
in pregnancy, 633-634, 672-674
in myocardial infarction, 409-436
acute, benefits of, 421
mortality with, 430
recommendations for, 431
- Calcium ion channel, slow, inotropic action on, 295-296
- Calculation, ability in, with cerebral infarction, 1362
- Caloric intake, in elderly, 1534
- Caloric restriction, effect on body composition, 231-233
response to, 102
- Cambridge diet, for obesity, 210
- Cancer, gastrointestinal, in elderly, emergency operations for, 1418
in obesity, 114
inconsistent findings in, 116
- Captopril, adverse effects of, 330
clinical efficacy of, 326, 328
effects on serum potassium, 325
effects on serum sodium, 323
for chronic congestive heart failure, hemodynamic effects of, 320
in breast milk, 601
nifedipine vs, 348
placebo vs, mean diastolic blood pressures in, 502
renal effects of, 324
side effects of, 330
- Carbamazepine, in breast milk, 599
in pregnancy, 664
- Carbohydrates, dietary, for elderly, 1536
intolerance to, in hemochromatosis, 836
role in obesity, 103-104
- Carbonic anhydrase inhibition, effects of, 272
- Carcinoma, evaluation for, with constipation, 1500
hepatocellular, 985-997. See also *Hepatocellular carcinoma*.
- Carcinomatosis, in elderly, emergency operation for, 1418
- Cardiac disease, in pregnancy, 639-651
counseling in, 640-642
labor and delivery management in, 648
- New York Heart Association classification of, 641

- Cardiac disorders, in neonatal lupus syndrome, 613
in pregnancy, 646-647
with Behçet's disease, 1241
with dermatomyositis, 1188-1189
- Cardiac muscle, contraction of, mechanical basis of, 284-287
- Cardiac output, decreased, and orthostatic hypotension, 1341
effect of nitrates on, 363
in measurement of cardiac performance, 291
in pregnancy, 639
- Cardiac performance, determinants of, 339
effect of cocaine on, 478-483
measurement of, 290-292
- Cardiac toxicity, catecholamine-mediated, beta-blocker therapy for, 374-375
- Cardiogenic embolism, and stroke, 1354-1356
treatment of, 1365
- Cardiomyopathy, congestive, nifedipine for, 345
dilated, and stroke, 1354
beta-blockers for, 377
ischemic, calcium antagonists for, 341
peripartum, in pregnancy, 646
- Cardiorespiratory complications, in amniotic fluid embolus, 735
- Cardiovascular alterations, in pre-eclampsia, 625
in pregnancy, 639-640
surgical implications of, 550
- Cardiovascular disease, in obesity, 112
inconsistent findings in, 116
risk factors for, exercise and, 217-219
with hypertension, in elderly, 1472
- Cardiovascular drugs, 271-516
and liver disease, 779, 787
clinical trials of, 495-509
clinical program of, 506-508
design problems in, 496-506
dose interval in, 507-508
dose response in, 506-507
interactions in, 508
titration in, 501-503
wrong assumptions in, 498-501
wrong incentives for, 497-498
in elderly, disposition of, 487-494
plasma lipid changes with, relevance of, 449-473
positive control studies of, 496-501
- Cardiovascular hemodynamics, effects of nifedipine on, 343
- Carotid endarterectomy, for stroke prophylaxis, 1363-1364
- Carpenter syndrome, and obesity, 166
- Catecholamines, chemical structures of, 302
for congestive heart failure, 301-303
increased, in heart failure, beneficial effects of, 374
harmful effects of, 375-376
neurotransmitters of, anorexiatic drug action on, 239-241
- Catheter, urinary, care of, 1450
problems with, 1446
- Catheterization. See *Urinary tract catheterization*.
- Causation, in medical liability, definition of, 561-562
- Ceftazidime, for urinary tract infections, 1445
- Ceftriaxone, for urinary tract infections, 1445
- Cell-mediated immunity, in primary biliary cirrhosis, abnormalities of, 916-917
- Central excitation, cocaine and, 478
- Central nervous system, anorexiatic drug action on, 239-244
role in falling, 1326, 1329
role in impotence, 1488
role in urinary incontinence, 1424
- Cephaloxacin, for urinary tract infections, 1445
- Cerebellar tremor, 1315-1316
- Cerebral angiography, in stroke evaluation, 1357-1358
- Cerebral cortex, fetal injury to, effects of, 526
- Cerebral edema, in fulminant hepatic failure, 959-960
- Cerebral infarction, in elderly, 1361-1362
- Cerebrospinal fluid, examination of, in acquired cognitive disorder, 1393
- Cerebrovascular accident, and urinary incontinence, 1424
with hypertension, in elderly, 1472
- Cervical spine, stenosis of, in elderly, 1374
- Cesarean delivery, and uterine infection, 713
in maternal diabetes, 694
morbidity with, 520
- Charcoal hemoperfusion, for fulminant hepatic failure, 965
- Chelation therapy, for hemochromatosis, 840
- Chenodeoxycholate, for gallstones, 763
- Chicken pox, breastfeeding in, 594
- Chilblain lupus, in systemic lupus erythematosus, 1103-1104
- Childhood, obesity in, 162
- Chlorambucil, cutaneous reactions to, 1292
for primary biliary cirrhosis, 921
- Chloroquine, cutaneous reactions to, 1284-1285
- Cholangiocarcinoma, in primary sclerosing cholangitis, 1014
- Cholangiography, intravenous, 760
percutaneous transhepatic, 761

- Cholangiopancreatography, endoscopic retrograde, 760-761, 901-902
- Cholangioscopy, peroral, 905-906
- Cholangitis, sclerosing, primary, liver transplantation for, 1014-1015
- Cholecystitis, in elderly, acute abdomen with, 1416-1418
- Cholecystography, oral, 759
- Choledocholithiasis, detection of, imaging for, 901
- Cholescintigraphy, 760
- Cholestasis, alcohol-induced, 820
- chronic, drug-induced, 777
- intractable, in primary biliary cirrhosis, 919-920
- intrahepatic, of pregnancy, 1043
- Cholesterol, effect of aging on, 1525-1526
- effect of centrally acting agents on, 462-465
- lowering of, 879-882
- lovastatin for, 437-448
- metabolism of, 438-439
- reverse transport of, 282
- synthesis of, 756, 864
- pathway of, 439
- Cholesterol gallstones, risk factors for, 754
- therapy for, 762, 765
- Cholestyramine, for pruritus, in primary biliary cirrhosis, 920
- Choline magnesium trisilicate, cutaneous reactions to, 1278
- Cholinergic hypothesis, of Alzheimer's disease, 1384-1385
- Cholinergic receptors, activation of, 1406
- Chorionic villus sampling, in fetal diagnosis, 530-531
- Chrysis, with gold therapy, 1286-1287
- Chylomicrons, metabolism of, 438-439
- production of, 863
- Circumference measurements, and health risks, 119
- for body fat determination, 7
- Cirrhosis. See also under *Liver disease*.
- alcoholic, 818-820
- drug-induced, 779-782
- in pregnancy, 1044-1045
- Cisapride, for chronic constipation, 1506
- Citrate, for hyperalimentation, 1546
- Clofibrate, for hypercholesterolemia, 881
- Clonazepam, in pregnancy, 664
- Clonidine, for hypertension in elderly, efficacy of, 1477
- for hypertension in pregnancy, 628-629, 672-674
- Clonorchiasis, and hepatocellular carcinoma, 1000-1001
- Coagulation factors, circulating, 725
- Coagulation studies, in stroke evaluation, 1357
- Coagulation system, intrapartum activation of, 727
- structure of, 723-724
- Coagulopathy(ies), abortion and, 736-737
- acquired, 738
- acute, in pregnancy, 723-743
- consumptive, with intrauterine fetal demise, 732
- hereditary, 737-738
- in fulminant hepatic failure, 960
- neonatal, maternal phenytoin therapy and, 572
- with abruptio placentae, 731
- with amniotic fluid embolus, 735-736
- with septic shock, 735
- Coarctation of aorta, in pregnancy, 644
- Cocaine, and coronary artery disease, 475-486
- cardiovascular complications of, 479-483
- chemical structure of, 476
- pharmacology of, 475-476
- Cognitive disorders, acquired, in elderly, 1383-1411
- clinical descriptions of, 1394-1400
- evaluation of, 1386-1394, 1407
- experimental approach to, 1405-1406
- management issues in, 1400-1408
- prevention of, 1401
- role in falls, 1330
- Cognitive factors, in food intake, in obesity, 53
- in medical compliance, 1559
- in weight control program, 60, 194
- Cogwheel phenomenon, in tremor, 1314
- Cohen syndrome, and obesity, 166
- Colchicine, for leukocytoclastic vasculitis, 1233
- for primary biliary cirrhosis, 921
- Colectomy, total, for pyoderma gangrenosum, 1257
- Colestipol, lovastatin with, 443
- Collagen, deposition of, in systemic scleroderma, 1174
- disorders of, penicillamine-induced, 1289-1290
- Collagen vascular diseases, 1055-1305
- with dermatomyositis, 1185
- Colon, cancer of, in obesity, 115
- perforated, in elderly, emergency operation for, 1418
- Common bile duct, stones in, 767-769
- stricture of, biliary stent for, 904
- Complement, deposits of, in cutaneous vasculitis, 1226-1227
- Comply, for hyperalimentation, 1546
- Conceptual age, and effect of drugs in breast milk, 588-589
- Confusional state, acute, clinical description of, 1399

- Congenital malformations, etiology of, 568
with maternal epilepsy, 663
- Congestive heart failure, angiotensin-converting enzyme inhibitors for, 320-322
beta-adrenergic blocking drugs for, 373-385
- chronic, digitalis for, 297-300
renin-angiotensin-aldosterone system in, 317-319
- endocrine changes in, 315-317
- hemodynamics in, effect of nitrates on, 363-365
- in hemochromatosis, 837
- inotropic agents in, 283-314
- neurohumoral changes in, 315-317
- nifedipine for, 344
- nitrates in, 361-371
effects on mortality, 367-368
rationale for, 361-362
tolerance to, 365-367
pathophysiology of, 292-297, 361-362
Starling curve in, 299
- Congophilic angiopathy, stroke vs, 1352
- Connective tissue disease, and Raynaud's phenomenon, 1130-1133
mixed, as variant of systemic scleroderma, 1178-1179
lupus hand test for, 1270
with leukocytoclastic vasculitis, 1228
- Constipation, in elderly, 1497-1509
chronic, stepped-care approach to, 1505-1506
drugs causing, 1499
evaluation of, 1500-1502
management of, 1501
pathophysiology of, 1498-1499
preventive therapy for, 1499-1500
stepped-care approach to, 1502-1505
- Consultant. See *Medical consultant*.
- Contraception, in diabetes, 696-697
in systemic lupus erythematosus, 606
- Contractility, chemical basis of, 286-290
- Contraction, mechanical basis of, 284-287
velocity of, 286-287
- Contractures, in juvenile dermatomyositis, 1199, 1201
- Control, locus of, in obesity, 52
- Converting enzymes, inhibition of, humoral effect of, 319-320
- Cor pulmonale, in amniotic fluid embolus, 735
- Cordocentesis, in fetal diagnosis, 532
- Coronary angioplasty, percutaneous transluminal, following thrombolysis, 401-402
- Coronary artery disease, cocaine-induced, 475-486
in pregnancy, 646
nifedipine for, 345
risk of, in elderly, lipid levels and, 1525-1530
plasma lipid transport and, 877-879
with myocardial infarction, and congestive heart failure, 293
- Cortical collecting tubule, diuretic action in, 274-275
- Cortical disorders, testing of, in acquired cognitive disorder, 1390
- Corticosteroids, cutaneous reactions to, 1283-1284
fetal effects of, 612
for asthma in pregnancy, 658
for chronic hepatitis B, 972-974
for cutaneous lupus erythematosus, 1068, 1085
for immunosuppression, in liver transplantation, 1026
for juvenile dermatomyositis, 1204-1205
for leukocytoclastic vasculitis, 1232-1233
for lupus erythematosus panniculitis, 1124
for primary biliary cirrhosis, 921
for pyoderma gangrenosum, 1257-1258
- Coumarin derivatives, teratogenic effects of, 571-572
- Creatinine clearance, in transplanted kidney, in pregnancy, 668
- Creatinine-height index, measurement of, in elderly, 1539-1540
- Crohn's disease, with pyoderma gangrenosum, 1253
- Cromolyn, for asthma in pregnancy, 658
- Cryoglobulinemia, with cutaneous necrotizing vasculitis, 1229
- Cryptorchidism, in Prader-Willi syndrome, 169
- Cushing's syndrome, with corticosteroids, 1283-1284
- Cutaneous hypersensitivity, testing of, for nutritional assessment, 1541
- Cutaneous immunofluorescence, in collagen vascular diseases, 1263-1274
- Cutaneous sclerosis, in systemic scleroderma, 1167
- Cutaneous vasculitis, 1221-1235
- Cyanosis, in acute asthma, 654
in Raynaud's phenomenon, 1133
- Cyclophosphamide, cutaneous reactions to, 1292
fetal effects of, 612
- Cyclosporine, and risk of malignancy, 675
cutaneous reactions to, 1292-1293
drug interactions with, 1025
fetal exposure to, 678-679
for immunosuppression, in liver transplantation, 1023-1026
for primary biliary cirrhosis, 921
toxicity of, in pregnancy, 671
- Cystitis, with urinary tract catheterization, 1447
- Cystometrics, bedside, 1433-1434
- Cytomegalovirus, fetal exposure to, 680

- Cytotoxic agents, cutaneous reactions to, 1290-1291
for pyoderma gangrenosum, 1258
- D-penicillamine, for primary biliary cirrhosis, 921
- Damage, in medical liability, definition of, 562
- Dapsone, for leukocytoclastic vasculitis, 1233
for pyoderma gangrenosum, 1257
- Debridement, for pressure ulcer treatment, 1520-1521
- Defensive medicine, practice of, 557
- Delayed gratification, in obesity, 51
- Delirium, and urinary incontinence, 1426
clinical description of, 1399
diagnostic criteria for, 1395
- Delivery, date of, determination of, 523
in cardiac disease, 648
in maternal diabetes, 693-694
premature, delay of, effects of, 522
- Delusions, in dementia, treatment of, 1404
- Dementia, and urinary incontinence, 1426
causes of, 1392
clinical description of, 1394-1399
degenerative, of Alzheimer's type, 1394-1396
diagnostic criteria for, 1395
intercurrent illness and, 1403
management of, principles in, 1402
multi-infarct, 1396-1398
resuscitation orders in, 1403
reversible, 1401-1402
treatment of, 1403-1405
- Denervation, pharmacologic, cocaine and, 477
- Densitometry, of bone minerals, 1458-1459
- Dependency, in obesity, 52
- Depigmentation, in systemic scleroderma, 1171
- Depression, and impotence, 1488-1489
and urinary incontinence, 1427
diagnostic criteria for, 1395
in dementia, treatment of, 1403
in obesity, 49
- Deprivation, in obesity, 50
- Dermatitis, lupus, photosensitive, 1095-1096
- Dermatomyositis, and malignancy, 1211-1226
research findings in, 1212-1214
as systemic disease, 1181-1192
association with pregnancy, 1190-1191
clinical manifestations of, 1212-1213
cutaneous manifestations of, 1181-1182, 1212-1213
diagnosis of, 1182, 1211
genetic predisposition to, 1216
juvenile, 1193-1209
clinical findings in, 1194-1201
cutaneous manifestations of, 1195-1199
diagnosis of, 1203-1204
epidemiology of, 1193-1194
etiology of, 1194
laboratory findings in, 1202
management of, 1204-1207
muscle manifestations of, 1199
pathology of, 1201-1202
prognosis in, 1207
lupus band test for, 1271
tumor types in, 1215
- Dermatosis(es), vascular, neutrophilic, 1237-1245
- Dermatitis-arthritis syndrome, bowel-associated, 1242
- Desferroxamine, for hemochromatosis, 840
- Desipramine, cathartic dosage of, 1504
- Detrusor instability, treatment of, 1435
- Developmental stage, interaction with environmental teratogen, 568
- Diabetes insipidus, nephrogenic, treatment of, 280
- Diabetes mellitus, and impotence, 1488
and pregnancy, 685-700
breastfeeding in, 594-597
contraception in, 696-697
in familial hyperlipoproteinemia, 873
in familial hypertriglyceridemia, 872
in hemochromatosis, 836
in obesity, 112, 126, 139
effect of surgery on, 258
etiologic mechanisms of, 127
in Prader-Willi syndrome, 169
in pregnancy, classification of, 687-688
diagnosis of, 687
fetal physiology in, 686
hospitalization vs outpatient care of, 693
management of, 696
obstetric management of, 695-696
lactation in, 595-597
lovastatin for, 444
milk composition in, 594
pregestational, classification of, 687
preconceptual counseling in, 688-689
- Diabetic nephropathy, effect of pregnancy on, 688
- Diabetic retinopathy, effect of pregnancy on, 689
- Dialysis, for fulminant hepatic failure, 963
- Diastolic function, effect of calcium antagonists on, 343
- Diazepam, in breast milk, 599
- Diazoxide, for acute hypertension in pregnancy, 631
- DIC. See *Disseminated intravascular coagulation*.
- Diclofenac, cutaneous reactions to, 1279

- Diet(s), and obesity, 20-22, 171-172
classification of, 204-205
composition of, for elderly, 1535-1536
for hyperlipidemia, 1528
effect on body composition, 232
for obesity, 203-215
in first trimester, in diabetics, 690
low calorie, 205-209
definition of, 203
for obesity, 203-215
types of, 204-205
with behavioral program for obesity, 196
very low calorie, 209-212
complications of, 211
contraindications to, 212
definition of, 203
for obesity, 203-215
monitoring in, 212
- Dietary fat, for elderly, 1535-1536
ratio to carbohydrates, role in obesity, 103
- Dietary fiber, deficiency of, and constipation, 1500-1503
for elderly, 1535-1536
for weight control, 208, 246
- Dietary fluid, in constipation treatment, 1503
- Diethylstilbestrol, teratogenic effects of, 575-576
- Diffusional, cutaneous reactions to, 1278
- Digital arteries, narrowing of, in Raynaud's phenomenon, 1129
- Digital ulcers, in systemic scleroderma, 1167
- Digitalis, 297-300
clinical response to, 300
effect on Starling curve, 299
hemodynamic effects of, 300
in breast milk, 601
inotropic effects of, 299
- Digoxin, loading dose of, 298
nifedipine vs, 348-349
pharmacokinetics of, 297-298
toxicity of, 298-299
- Dihydropyridines, second-generation, for heart failure, 351-353
- Diltiazem, effect on heart rate, 342
for acute myocardial infarction, clinical studies of, 427-429
results with, 430
nifedipine vs, 350-351
- Diphenylhydantoin, for weight control, 243
- Disc herniation, in elderly, 1375
- Disclosure, physician's duty of, 559
- DISH. *See Skeletal hyperostosis, diffuse idiopathic.*
- Disseminated intravascular coagulation, amniotic fluid embolus and, 735-736
causes of, 730-737
eclampsia and, 736
- fetal, in multiple gestations, 734
hemolytic uremic syndrome and, 737
in pregnancy, 727-737
diagnosis of, 728
management of, 728-729
trigger mechanisms for, 730-737
pre-eclampsia and, 736
sepsis and, 734-735
with abruptio placentae, management of, 731
with intrauterine fetal demise, 732-734
- Distal tubule, diuretic action in, 274-275
- Disulfiram, and liver disease, 788
- Diuretics, 271-282
clinical trials of, titration in, 501
for hypertension, in elderly, 1475-1476
in pregnancy, 628
in breast milk, 600
loop, 273-274, 277
nonthiazide, effect on serum lipids, 454
pharmacology of, nephron physiology and, 272
physiology of, new directions in, 280-281
plasma lipid changes with, 450-453
side effects of, 278
sites of action of, 271-275
therapy with, consequences of, 272
issues in, 275-276
- Diverticulitis, in elderly, acute abdomen with, 1416-1417
- Dobutamine, for congestive heart failure, 303
- Dopamine, for congestive heart failure, 302
- Dopaminergic medication, for Parkinson's disease, 1313
- Doppler ultrasound, in fetal diagnosis, 533-534
- Dose-response relationship, interaction with environmental teratogen, 568
- Doxepin, cathartic dosage of, 1504
- Dressings, for pressure ulcer treatment, 1521
- Drop attacks, role in falls, 1329
- Drug trials, clinical, dose intervals in, 507-508
dose-response in, 506-507
design problems in, 496-506
drug toxicity in, 502
ethical considerations in, 505-506
interactions in, 508
statistical analysis of, failure of, 497
wrong assumptions in, 498-501
wrong incentives for, 497-498
- Drugs, allergy to, signs of, 784
and constipation, 1499
and hepatocellular carcinoma, 1003-1006
and impotence, 1487-1488
and tremor, 1316
and urinary incontinence, 1427
as cause of obesity, 172-173

Drugs (Continued)

- clearance of, in elderly, 488
- effectiveness of, determination of, 498
- effects on fetus, 570, 611-613
- effects on nutrient absorption, 1533
- for hepatic encephalopathy, 807
- for obesity, 237-249
- in elderly, response to, mechanisms of, 487-491
- in lactation, 588-589
- interaction with environmental teratogen, 568
- metabolism of, alcohol and, 786
- and liver disease, 785-786
- noncompliance with, in elderly, 1554, 1557
- oral nonbioavailability of, 590
- placental transport of, 569
- role in falls, 1329
- Duodenal ulcer, in elderly, acute abdomen with, 1416
- Duty, in medical liability, definition of, 558-559
- Dyslipoproteinemia, 871-872
 - in obesity, effect of surgery on, 258
- Dysphagia, in dermatomyositis, 1183, 1189
- Dyspnea, in acute asthma, 655

- Ear, in discoid lupus erythematosus, 1056, 1059
- Eating. *See Food intake.*
- Eating style, in obesity, 54-56
- Eclampsia, and disseminated intravascular coagulation, 736
 - and liver dysfunction, 1044
 - seizures in, 626, 662
- Eisenmenger's syndrome, in pregnancy, 645
- Ejection fraction, following thrombolytic therapy reperfusion, 398
 - in measurement of cardiac performance, 291
- Elastosis perforans serpiginosa, penicillamine-induced, 1290
- Elderly. *See also Aging.*
 - acute abdomen in, 1413-1422
 - cardiovascular drugs in, disposition of, 487-494
 - cognitive disorders in, 1383-1411
 - coronary heart disease risk in, 1525-1530
 - falls in, 1321-1336
 - hypertension in, 1471-1481
 - medication compliance in, 1551-1563
 - nutrition in, 1531-1549
 - orthostatic hypotension in, 1337-1349
 - osteoporosis in, 1455-1470
 - pressure ulcers in, 1511-1524
 - propranolol use in, 489-491
 - rheumatic syndromes in, 1371-1381
 - sexual function in, 1483-1495
 - stroke in, 1351-1369
 - tremors in, 1307-1319
 - urinary incontinence in, 1423-1439
 - urinary tract catheterization in, 1441-1454
- Electrocardiogram, in acute abdomen, 1415-1416
- Electroencephalography, for hepatic encephalopathy, 795-796
 - in acquired cognitive disorder, 1393
 - in stroke evaluation, 1356
- Electrolytes, altered, in acute abdomen, 1415-1416
 - disorders of, in fulminant hepatic failure, 961
 - effects of angiotensin-converting enzyme inhibitor on, 323-325
 - monitoring of, in hyperalimentation, 1547
 - patterns of excretion of, 271-275
- Electromyography, in dermatomyositis, 1184-1185
- Embryopathy, warfarin, 571
- Emotional stress, in renal transplant patients, in pregnancy, 675
- Enalapril, adverse effects of, 330-331
 - clinical efficacy of, 326
 - decreased serum sodium with, 323
 - effects on serum potassium, 325
 - for chronic congestive heart failure, hemodynamic effects of, 320
 - renal effects of, 324
 - side effects of, 330
- Encephalitis, clinical description of, 1399-1400
- Encephalopathy, hepatic, 793-813. *See also Hepatic encephalopathy.*
- Endocarditis, bacterial, prophylaxis for, at delivery, 648
- Endocrine disorders, and impotence, 1488
 - and obesity, 113, 139-160
 - and urinary incontinence, 1427
- Endocrine pancreas, in obesity, 139-141
- Endometrial cancer, in obesity, 114
- Endometritis, 714-715
- Endoscopy, emergency, in esophageal varices, 944
 - techniques of, advanced, 895-909
- Enemas, for chronic constipation, 1506
- Energy expenditure, and body weight set-point, 17-19
 - effect of chronic exercise on, 227-233
 - elements of, 97-100
 - for recreational activities, 1534
 - genetics and, 75
 - in body weight regulation, 15-17
 - in elderly, 1541-1542
 - in obesity, 69, 97-110, 219-227
 - limits of, 97-100
- Energy intake, genetics and, 75
 - in body weight regulation, 15-17

- Enigmatic fever, pelvic vein thrombophlebitis in, 717
- Ensure, for hyperalimentation, 1546
- Enteral hyperalimentation, for protein-calorie malnutrition, 1544
- products for, 1545
- Environment, role in falls, 1328, 1333
- Enzyme inhibitors, for weight control, 246
- Eosinophilia, in localized scleroderma, 1149-1150
- Eosinophilic fasciitis, 1157-1166. See also under *Fasciitis*.
- Ephedrine, for weight control, 244
- Epilepsy, breastfeeding in, 598-599
- in pregnancy, 661-665
- Epinephrine, for acute asthma in pregnancy, 656
- Episiotomy infection, life-threatening, 718-719
- Erectile dysfunction. See *Impotence*.
- Erythema, periungual, in systemic lupus erythematosus, 1103
- Erythema nodosum, 1242-1243
- Esophageal varices, hemorrhage of, 941-947
- management of, 943-945
- mechanism of, 941-943
- prevalence of, 940
- prevention of, 945-947
- prognosis in, 943
- natural history of, 941-943
- pharmacologic therapy of, 946
- pressure measurement of, 939-940
- surgery for, 945
- Essential tremor, in elderly, 1310-1312
- Parkinsonian signs in, 1315
- Estrogen, and hepatocellular carcinoma, 1003-1004
- and sexual function, in aging females, 1492
- for osteoporosis, 1462-1464
- in pregnancy, effect on seizure disorders, 661
- effect on systemic lupus erythematosus, 606
- Ethanol, metabolism of, 815-816
- Ethical considerations, in drug trials, 505-506
- Ethosuximide, in breast milk, 599
- Euglycemia, in diabetes, maintenance during delivery, 695
- Evoked responses, for hepatic encephalopathy, 795-796
- Exercise, and cardiovascular disease risk factors, 217-219
- and obesity, 217-236
- and thermic effect of food, 101, 223-227
- effects of, 227-233
- on body composition, 232
- on food intake, 228-230
- psychological, 233
- thermic, 97
- energy expenditure in, 221-223, 228
- for hypertension in elderly, 1474
- for orthostatic hypotension, 1345
- for osteoporosis, 1465-1466
- improved capacity for, with angiotensin-converting enzyme inhibitors, 326
- in weight control program, 107, 193
- techniques of, 191
- tolerance for, in congestive heart failure, effect of nitrates on, 363-365
- Exercise training, effects of, 227-228, 230-233
- Expert witness, in malpractice case, role of, 561
- Extracorporeal shock wave lithotripsy, for gallstones, 765-766
- Eyesight, changes in, role in falling, 1326-1327
- Falls, in elderly, 1321-1336
- aging process and, 1324-1327
- clinical approach to, 1330-1333
- death from, 1321-1322
- epidemiology of, 1321-1323
- etiology of, 1327-1330
- sequelae to, 1323-1324
- treatment of, 1333-1334
- Familial Mediterranean fever, 1243
- Fasciitis, eosinophilic, 1157-1166
- as variant of systemic scleroderma, 1177
- biopsy for, 1162
- clinical features of, 1158-1161
- course of, 1163
- cutaneous manifestations of, 1158-1159
- etiology of, 1163-1164
- extracutaneous manifestations of, 1158-1159
- hematologic associations with, 1160-1161
- laboratory findings in, 1161
- localized scleroderma vs, 1151-1152
- pathology of, 1162-1163
- therapy for, 1163
- visceral involvement in, 1160
- necrotizing, postpartum, signs of, 718
- Fat, dietary, for elderly, 1535
- role in obesity, 103
- distribution of, in obesity, 162
- percentiles for, 164
- regional, for measurement of overweight, 175
- regional, mobilization of, 248
- storage of, factors promoting, 103-105
- total body, 31
- topography of, definition of, 68
- Fat cells, 83-96. See also *Adipose tissue*.
- number of, for measurement of overweight, 175

- Fat cells (*Continued*)
 number of, in obesity, 161-162
 nutritional regulation of, 90
 size of, for measurement² of overweight, 175
 nutritional regulation of, 89-90
- Fat-to-carbohydrate ratio, in diet, role in obesity, 103
- Fatty acids, in adipose tissue, 84
- Fatty liver, alcoholic, 817-818
 of pregnancy, 1043-1044
 and disseminated intravascular coagulation, 737
- Feedback signals, of nutrient balance, 34-36
- Feeding. *See Food intake.*
- Feeding formulas, for protein-calorie malnutrition, 1544
- Felodipine, for heart failure, 352-353
- Females, sexual function in, with aging, 1491-1492
- Fenoprofen, cutaneous reactions to, 1280
- Ferric molecules, uptake of, mechanisms of, 835
- Ferritin, serum levels of, in hemochromatosis, 834
- Fertility, in human immunodeficiency virus infection, 703
 in systemic lupus erythematosus, 605-606
- Fetal AIDS syndrome, 704
- Fetal alcohol syndrome, 571
- Fetal assessment, biochemical, 535-536
 technology of, 529-538
- Fetal death, definition of, 518
 intrauterine, and disseminated intravascular coagulation, 732-733
 with maternal renal transplant, 675-676
 with maternal systemic lupus erythematosus, 608
- Fetal distress, in labor, prediction of, 538
- Fetal heart rate, and fetal status, 536
- Fetal hydatoin syndrome, 572
- Fetal monitoring, electronic, external, 536-537
 in diabetes, in third trimester, 692-693
- Fetal movement, maternal perception of, 536
- Fetal trimethadione syndrome, 573
- Fetal valproate syndrome, 573
- Fetor hepaticus, in hepatic encephalopathy, 796
- Fetus. *See also under Fetal.*
 as patient, 517-540
 drug effects on, 570
 effect of maternal disease on, 546
 high-risk index for, 527-529
- Fever, enigmatic, pelvic vein thrombophlebitis in, 717
 in pyogenic liver abscess, 849
 persistent, in endometritis, 715-716
- Fiber, dietary, for weight control, 208, 246
- Fibrin, deposits of, in cutaneous vasculitis, 1226-1227
- Fibrinogen, in coagulation system, 724
 levels of, with thrombolytic therapy, 395
- Fibrinolytic agents, for Raynaud's phenomenon, 1138-1139
- Fibrinolytic system, activity of, 727
- Filling pressures, in cardiac performance, 291
- Fludrocortisone, for orthostatic hypotension, 1345
- Fluid intake, in elderly, 1533-1534
- Fluid retention, in hepatic encephalopathy, 796
- Fluid therapy, for acute asthma in pregnancy, 657
- Fluoride, for osteoporosis, 1466
- Flurbiprofen, cutaneous reactions to, 1281
- Foam pads, for pressure ulcer treatment, 1517
- Food, caloric density of, in obesity, 56
 intake of. *See Food intake.*
 thermic effect of, exercise and, 97, 101, 223-226
- Food intake, control of, for obesity, 53-54
 in humans, 29-45
 effect of exercise on, 228-230
 in obesity, 53-55, 103, 171
 relationship to fat cell size, 89
 signals affecting, 34, 37
 thermic response to, 100
- Foot care, fall prevention by, 1333
- Forgetfulness, benign senescence, 1387
- Formula diets, for obesity, 205, 208-209
- Fractures, in elderly, 1372
 with falls, 1323
 in osteoporosis, prevention of, 1456
- Free radical scavengers, for alcoholic liver disease, 825
- Friction, and pressure ulcers, 1514
- Froment's sign, in tremor, 1314
- Functional assessment, in acquired cognitive disorder, 1388, 1391
- Functional residual volume, in pregnancy, 654
- Furosemide, for hypercalcemia, 278-279
 for hyponatremia, 280
- GABA/benzodiazepine receptor complex, in hepatic encephalopathy, 802-804
- Gait, in elderly, effect on falling, 1325-1326, 1332
- Galactogenesis, initiation of, 586
- Galactopoiesis, in lactation, 584
- Gallstones, computed tomography of, 760
 diagnosis of, 758-761
 environmental factors in, 754
 epidemiology of, 753-754

- formation of, 757-758
- imaging of, 899-901
- laser lithotripsy of, 906
- oral therapy for, 762-764
- pathophysiology of, 754-758
- recurrence and prevention of, 769
- therapy for, 761-769, 906
- types of, 753
- Gangrene, digital, in systemic lupus erythematosus, 1104
- postpartum, 718-719
- Gastric bypass, complications of, 260
- for weight control, 256-257
- Gastric emptying, inhibitors of, for weight control, 247
- Gastric paresis, in diabetes, effect of pregnancy on, 689
- Gastric restriction, in weight control, 254
- Gastrointestinal alterations, in pregnancy, surgical implications of, 550
- Gastrointestinal disorders, in Behçet's disease, 1241
 - in cutaneous vasculitis, 1226
 - in dermatomyositis, 1189-1190
 - in juvenile dermatomyositis, 1200
 - in systemic scleroderma, 1171-1172
- Gastrointestinal signals, of nutrient balance, 35
- Gastrointestinal tract, drugs affecting, for weight control, 245-247
- Gastropathy, portal hypertensive, 947
- Gastroplasty, for weight control, 253, 257
- Gemfibrozil, for hypercholesterolemia, 881
- for hyperlipidemia, 1528
- Genetic diseases, liver transplantation for, 1016-1017
- Genetic theory, of Alzheimer's disease, 1385
- Genetics, and adaptation to chronic overfeeding, 76-78
 - and body fat, 71-75
 - and energy expenditure, 75
 - in obesity, 67-81, 165-169
- Genital tract infection, in pregnancy, 713
- Geriatric medicine, 1307-1563
- Gestational age, as predictor of morbidity and mortality, 523
- ultrasonic determination of, 524
- Glomerular filtration rate, in congestive heart failure, 323
- in pregnancy, 669-671
- Glucagon, for alcoholic liver disease, 825
- Glucocorticoids, for acute asthma in pregnancy, 657
- for alcoholic liver disease, 824
- Glucose, effect of body fat distribution on, 122-126
- Glucose tolerance, abnormal, in familial hypertriglyceridemia, 872
- and cardiovascular disease risk factors, 218
- Glycemic control, in first trimester, in diabetics, 689-690
- Gold, cutaneous reactions to, 1285-1288
- Gorging, nibbling vs, in lipogenesis, 105
- Gotttron's papules, in dermatomyositis, 1181, 1183, 1212
 - in juvenile dermatomyositis, 1195, 1197
- Graft rejection, in liver transplantation, 1024
- Granulomatosis, allergic, with cutaneous granulomatous vasculitis, 1230
- Graves' disease, breastfeeding in, 597
- Growth hormone, for weight control, 245
- reduced, in obesity, 141-143, 170
- Guarding, involuntary, in acute abdomen, 1414
- Cut, changes in, age-related, 1498-1499
- Gynecologic tumors, in dermatomyositis, 1214
- Hallucinations, in dementia, treatment of, 1404
- Halothane, metabolism of, and liver disease, 785-786
- Harm, in medical liability, definition of, 562
- Head trauma, and tremor, 1316
- Health risks, of obesity, 111-138
 - inconsistent findings in, 115-118
- Heart. See also under *Cardiac*; *Cardio*; *Coronary*.
 - Heart disease, breastfeeding in, 599-601
 - congenital, in pregnancy, 643-644
 - Heart failure, angiotensin-converting enzyme inhibitors in, 315-338
 - beta-blockers for, 377
 - calcium antagonists and, 339-359
 - congestive. See *Congestive heart failure*.
 - Heart muscle, effect of cocaine on, 478-483
 - microscopic structure of, 285
 - Heart rate, effect of calcium antagonists on, 342-343
 - effect of cocaine on, 479
 - in acute asthma, 655
 - Heart valves, prosthetic, and stroke, 1354
 - in pregnancy, 647-648
 - Height, change in, in elderly, 1537
 - in body fat determination, 3
 - Heliotrope rash, in dermatomyositis, 1181, 1183, 1212
 - in juvenile dermatomyositis, 1196
 - Hemangioma, cavernous, imaging of, 900
 - Hematologic abnormalities, in neonatal lupus syndrome, 613
 - with dermatomyositis, 1190
 - Hematologic alterations, in pregnancy, surgical implications of, 550
 - Hematologic malignancy, with pyoderma gangrenosum, 1254

- Hematoma, with recombinant tissue-type plasminogen activator therapy, 394
- Hematuria, in cutaneous vasculitis, 1225
- Hemochromatosis, 831-845
and hepatocellular carcinoma, 1003
idiopathic, 832-836
liver transplantation for, 1017
secondary, 838-839
therapy for, 839-840
- Hemodialysis, and secondary hemochromatosis, 838
- Hemolytic uremic syndrome, and disseminated intravascular coagulation, 737
- Hemophilia, coagulopathy in, 738
liver transplantation for, 1017
- Hemorrhage, in stroke, 1352
intracerebral, treatment of, 1365-1366
postpartum, with abruptio placentae, 732
with thrombolytic therapy, 395
- Hemosiderosis, in hemochromatosis, 832
- Henle's loop, thick ascending limb of, diuretic action in, 273
- Henoch-Schonlein purpura, as hypersensitivity vasculitis, 1229
- Heparin, for stroke, 1362-1363
in thrombolytic therapy, 391
- Hepatic. See also *Liver*.
- Hepatic diseases, 753-1053
- Hepatic encephalopathy, 793-813, 943, 959
acute, clinical staging of, 959
treatment of, 805
assessment of, 794-796
associated findings in, 796-797
diet for, 806-807
etiology of, 797
laboratory tests of, 795
manifestations of, 793
neuropathology of, 799
pathogenesis of, 800-804
precipitating factors in, 797-798
prognosis in, 798-799
stages of, 794
treatment of, 804-807
- Hepatic enzymes, elevation of, drug-induced, 776
- Hepatic failure, acute, definition of, 955-956
degree of, assessment of, 943
fulminant, 955-970
complications of, 959-962
course of, 965-966
definition of, 955-956
etiology of, 956-957
liver transplantation for, 1019-1020
management of, 962-966
pathology of, 957-959
prognosis in, 966-967
- Hepatic vein, catheterization of, for portal pressure measurement, 937
thrombosis of, liver transplantation for, 1018-1019
- Hepatitis, alcoholic, 817-819
antigens of, in hepatocellular carcinoma, 986
breastfeeding in, 593
chronic, alcohol-induced, 820-821
and hepatocellular carcinoma, 999-1000
differential diagnosis of, 972
liver transplantation for, 1015-1016
delta, 978-979
drug-induced, frequency of, 776
viral, and fulminant hepatic failure, 956
chronic, 971-983
in pregnancy, 1041-1043
nonA, nonB, 979-980
- Hepatitis B, chronic, acyclovir for, 976
combination therapy for, 977-978
corticosteroids for, 972-974
interferon for, 974-975
levamisole for, 976
liver transplantation for, 1015
prednisone for, 978
ribavirin for, 976
transfer factor for, 977
treatment of, 971-972
vidarabine for, 975
- Hepatitis B virus, and hepatocellular carcinoma, 985
DNA of, integrated, 991-992
genomic DNA map of, 987-988
- Hepatitis D virus, 978-979
- Hepatobiliary dysfunction, following liver transplantation, 1027-1029
- Hepatocellular carcinoma, 985-997
alcohol-induced, 821
conditions associated with, 999-1009
growth of, 992-993
hepatitis B virus-related, 986-991
pathogenesis of, 989-993
liver transplantation for, 1017-1018
risk factors for, 991
with primary biliary cirrhosis, 912
- Hepatocellular necrosis, acetaminophen-induced, 958
in fulminant hepatic failure, 957
- Hepatoma cell line, analysis of, 990
- Hepatomegaly, in pyogenic liver abscess, 849
- Hepatorenal syndrome, liver transplantation for, 1018
- Hepatosplenomegaly, in familial hyperlipoproteinemia, 873
- Hepatotoxins, acute, classification of, 780-781
clinical syndromes caused by, 776
idiosyncratic, and liver disease, 784-785
intrinsic, and liver disease, 783-784
- Heredity. See *Genetics*.
- Hernia, incarcerated, in elderly, acute abdomen with, 1416-1418
- Herpes encephalitis, clinical description of, 1399

- Herpes simplex, breast-feeding in, 593-594
- High-fiber diets, for obesity, 204, 207-208
- High-protein diets, for obesity, 205
- Hip fracture, and pressure ulcers, 1513
- incidence of, 1456
- Holter monitoring, in stroke evaluation, 1357
- Hormones, derivatives of, and liver disease, 778
- for weight control, 247-248
- imbalances of, in obesity, 127
- in nutrient balance, 35
- levels of, in female obesity, 145
- in male obesity, 143-144
- Human chorionic gonadotropin, for obesity, 247
- Human immunodeficiency virus, fetal exposure to, 679-680
- infection with. *See Human immunodeficiency virus infection.*
- prenatal screening for, 707-708
- Human immunodeficiency virus infection, breastfeeding in, 593
- in pregnancy, 701-711
- care of, 706-707
- effect of pregnancy on, 705-706
- effect on pregnancy, 703-705
- seroprevalence of, 702-703
- perinatal transmission of, 703-705
- pregnancy prevention in, 706
- Humoral immunity, abnormalities of, in primary biliary cirrhosis, 916
- Hyaline degeneration, in lupus erythematosus panniculitis, 1117-1119
- Hydralazine, for hypertension in pregnancy, 630-631, 672-674
- nifedipine vs, 348
- Hydrocephalus, normal pressure, and urinary incontinence, 1424
- dementia in, 1398-1399
- Hydrochlorothiazide, and subacute cutaneous lupus erythematosus, 1087
- plasma lipid changes with, relevance of, 450
- Hydroxychloroquine, cutaneous reactions to, 1284-1285
- for eosinophilic fasciitis, 1163
- for subacute cutaneous lupus erythematosus, 1085
- Hyperalimentation, for protein-calorie malnutrition, 1544
- assessment of, 1547
- Hyperbilirubinemia, in infants of diabetic mothers, 687
- Hypercalcemia, furosemide for, 278-279
- Hypercalciuria, idiopathic, thiazides for, 278
- Hypercholesterolemia, 1527-1529
- familial, 869-870
- lovastatin for, 442-444
- polygenic, 871
- Hypergammaglobulinemia, in localized scleroderma, 1150
- Hyperglycemia, in hemochromatosis, 836
- in obesity, 141
- monitoring of, in hyperalimentation, 1547
- thiazide-induced, 450
- Hyperinsulinemia, in hemochromatosis, 836
- in obesity, 139, 170
- Hyperlipidemia, multiple lipoprotein-type, 870-871
- thiazide-induced, 450
- treatment of, 1528
- Hyperlipoproteinemia(s), 859-893
- classification of, 865
- combined, 870-871
- familial, 871-874
- laboratory testing for, 875-877
- lipoprotein patterns in, classification of, 867
- primary, 866-874
- secondary, 874-875
- diseases associated with, 869
- treatment of, 879-882
- Hyperosmotic agents, for chronic constipation, 1505-1506
- Hyperparathyroidism, in obesity, 148
- Hyperpigmentation, in hemochromatosis, 836
- with gold therapy, 1287
- Hypertension, and impotence, 1487
- and lacunar infarction, 1353
- breastfeeding in, 599-601
- chronic, pre-eclampsia vs, 624
- definition of, 623
- drugs for, clinical trials of, 501
- in elderly, 1471-1481
- incidence of, 1471-1472
- isolated systolic, 1473
- nonpharmacologic therapy of, 1474
- pathophysiology of, 1472-1473
- pharmacologic therapy of, 1474-1475
- adverse effects of, 1477-1478
- prevalence of, 1471-1472
- risks of, 1472
- treatment recommendations for, 1479
- in obesity, 149
- effect of surgery on, 258
- in pregnancy, crisis in, 623-638
- in renal transplant patients, 672-674
- therapy of, 628-634
- medication compliance in, 1553
- portal, 931-953
- classification of, 934
- diagnostic approach to, 947-948
- drug-induced, 782
- drugs for, 946
- etiology of, 931-933
- gastropathy in, 947
- nonvariceal bleeding in, 947
- pathophysiology of, 932-935

- Hypertension (*Continued*)
 portal, patient evaluation in, 935-941
 therapeutic approach to, 947-948
 systemic, myocardial infarction prevention in, 410-411
 therapy of, diuretics in, 277-278
- Hyperthyroidism, breastfeeding in, 597
- Hypertriglyceridemia, familial, 872-873
- Hyperuricemia, in familial hyperlipoproteinemia, 873
- Hyperventilation, for fulminant hepatic failure, 963
 in pregnancy, 653
- Hypoalbuminemia, and pressure ulcers, 1513
 in protein-calorie malnutrition, 1543
 in pyogenic liver abscess, 849
- Hypoaldosteronism, primary, in hemochromatosis, 837
- Hypocalcemia, in infants of diabetic mothers, 687
- Hypofibrinogenemia, with intrauterine fetal demise, 732-733
- Hypoglycemia, in fulminant hepatic failure, 961
 in infants of diabetic mothers, 686
- Hypogonadism, in hemochromatosis, 836
 with aging, 1484
- Hyponatremia, development of, diuretics and, 276
 treatment of, 279-280
- Hypotension, autonomic, in elderly, treatment of, 1344-1346
 in fulminant hepatic failure, 960
 orthostatic, in elderly, 1337-1349
 age as risk factor for, 1340-1341
 atypical syndromes of, management of, 1346-1347
 criteria for, 1338
 differential diagnosis of, 1341-1342
 epidemiology of, 1337-1338
 evaluation of, 1343-1344
 medications associated with, 1343
 with angiotensin-converting enzyme inhibitors, 330
 with nifedipine, 346
 with thrombolytic therapy, 395
- Hypothalamic obesity, 22-23, 172
- Hypothalamic-pituitary-adrenal axis, in obesity, 146-147
- Hypothalamic-pituitary-testicular axis, changes with aging, 1485
- Hypothyroidism, breastfeeding in, 597
 with primary biliary cirrhosis, 913
- Hypovolemia, in esophageal varices, 944
 in fulminant hepatic failure, 960
- Hypoxemia, arterial, in fulminant hepatic failure, 961
- Hypoxia, fetal sensitivity to, 525
- Hysterectomy, and sexual function, in aging females, 1492
- Hysterical tremor, 1317
- Ibuprofen, cutaneous reactions to, 1280
- Idiopathic thrombocytopenic purpura, in pregnancy, case history of, 553-554
- Immobiity, and pressure ulcers, 1513
- Immune complexes, in vasculitis, 1223
- Immune disorders, in dermatomyositis, with malignancy, 1216
 in juvenile dermatomyositis, 1194
 in leukocytoclastic vasculitis, 1228
 in primary biliary cirrhosis, 916-917
 in systemic scleroderma, 1174
- Immunity, cell-mediated, in pyoderma gangrenosum, 1251-1252
- Immunofluorescence, cutaneous, in collagen vascular diseases, 1263-1274
 direct, preparation of, 1264
 in pyoderma gangrenosum, 1251
- Immunoglobulins, elevated, in leukocytoclastic vasculitis, 1231
 in primary biliary cirrhosis, 913
 in chronic cutaneous lupus erythematosus, 1065-1066, 1265
- Immunosuppressive agents, and liver disease, 779
 fetal exposure to, 676
 for pyoderma gangrenosum, 1258
 for systemic scleroderma, 1176
 for systemic vasculitis, 1233
- Impotence, with aging, 1485-1489
 drugs associated with, 1488-1489
 etiology of, 1486-1489
 management of, 1489-1491
- Inactivity, and obesity, 170-171
- Indomethacin, cutaneous reactions to, 1278
- Infant mortality, definition of, 518
- Infection, and hepatocellular carcinoma, 999-1001
 and urinary incontinence, 1427
 following liver transplantation, 1030-1032
 in fulminant hepatic failure, 961
 in renal transplant patients, in pregnancy, 674-675
 protection against, breastfeeding and, 583
 severe, in pregnancy, 713-721
 with cutaneous necrotizing vasculitis, 1228
- Infection theory, of Alzheimer's disease, 1386
- Infectious disease, breastfeeding in, 591-594
- Inflammatory bowel disease, in primary sclerosing cholangitis, 1014
- Informed consent, in medical liability, 558
 standards of, 560
- Inhalers, for asthma in pregnancy, 658

- Inotrope(s), chemical structure of, 294
 classes of, 295
 definition of, 283
 effects of, measurement of, 292
 for congestive heart failure, 283-314
 in muscle contraction, 289-290
 nondigitalis, 301-307
 pharmacologic, action of, 293-297
- Insomnia, in dementia, treatment of, 1404
- Inspiratory reserve volume, in pregnancy, 654
- Insulin, and nutrient balance control, 38
 dynamics of, body fat distribution and, 122-123
 for alcoholic liver disease, 825
 for diabetic patient, 696
 during delivery, 695
 in first trimester, 690
 resistance to, in obesity, 140
 role in lactation, 586
 sensitivity to, and cardiovascular disease risk factors, 218
- Insulin-like growth factor I, in adipocyte differentiation, 92
- Interferon(s), for chronic hepatitis B, 974-975
 for hepatic encephalopathy, 807
- Internal malignancy, with pyoderma gangrenosum, 1254
- Interstitial lung disease, with dermatomyositis, 1186-1188
- Intestinal bypass, complications of, 260-261
 for weight control, 253
- Intestinal obstruction, in elderly, acute abdomen with, 1416-1418
- Intestinal transit time, in constipation, 1498-1499
- Intracranial pressure, increased, in fulminant hepatic failure, 959-960
- Intrahepatic duct, stones in, 767-769
- Intrauterine fetal demise, and disseminated intravascular coagulation, 732-734
- Iodine, radioactive, teratogenic effects of, 575
- Iron, accumulation of, pathways of, 835
- Ischemia, beta-blockers for, 415-416
 in stroke, 1352-1356
- Ischemic cardiomyopathy, calcium antagonists for, 341
- Isoniazid, metabolism of, and liver disease, 786
- Isoproterenol, for acute asthma in pregnancy, 657
 for congestive heart failure, 301
- Isosorbide dinitrate, for congestive heart failure, 364-365
 nifedipine vs, 347
- Isotein HN, for hyperalimentation, 1545
- Isotretinoin, teratogenic effects of, 576
- Isradipine, for heart failure, 353
- Jakob-Creutzfeldt disease, dementia in, 1398
- Jaundice, drug-induced, 776
 in hepatic encephalopathy, 796
 in primary biliary cirrhosis, 911
 obstructive, and secondary hyperlipoproteinemia, 874
- Jejunoileal bypass, for weight control, 255
- Jevity, for hyperalimentation, 1545
- Joint disorders, in dermatomyositis, 1186
 in eosinophilic fasciitis, 1159
- ⁴⁰K counting, for body fat determination, 2
- Kallikrein-kinin system, 317
- Ketoacidosis, in diabetes, in third trimester, 692
- Ketogenic diets, for obesity, 207
- Ketoprofen, cutaneous reactions to, 1281
- Kidney, alterations in, in pregnancy, surgical implications of, 550
 dysfunction of, following liver transplantation, 1033
 effects of angiotensin-converting enzyme inhibitor on, 323-325
 function of, and clinical efficacy of angiotensin-converting enzyme inhibitors, 327, 330
 testing of, in first trimester, in diabetics, 690
- Kidney disease, in dermatomyositis, 1190
 in leukocytoclastic vasculitis, 1231
 in subacute cutaneous lupus erythematosus, 1079
 in systemic scleroderma, 1172
 progression of, in pregnancy, 671
- Kidney failure, acute, diuretics in, 275-276
 in fulminant hepatic failure, 961
- Kidney transplant patients, pregnancy counseling of, 680-681
 pregnancy outcome in, 675-676
- Korsakoff's syndrome, clinical description of, 1399
- Labetolol, effect on plasma lipids, 457
 effect on serum lipids, 461
 for hypertension in pregnancy, 629-630, 672-674
- Labor, management of, in cardiac disease, 648
 premature, tocolytic therapy for, 524
- Lactation, drugs in, 588-589
 energy utilization in, 586-587
 enhancement of, drugs for, 590
 in diabetics, insulin dosage during, 595
 medical illness in, general management of, 588-591
 physiology of, 584-588
 suppression of, drugs for, 590

- Lactilol, for hepatic encephalopathy, 806
- Lactogenesis, in lactation, 584
- Lactulose, for chronic constipation, 1504, 1506
for fulminant hepatic failure, 962
for hepatic encephalopathy, 806
- Lacunar infarction, in stroke, 1353-1354
treatment of, 1365
- Language, testing of, in acquired cognitive disorder, 1390
- Latex catheters, for urinary tract catheterization, 1442
- Laxatives, irritant, avoidance in constipation, 1502
cathartic dosage of, 1504
classes of, 1499, 1502
- Left-to-right shunts, in pregnancy, 644
- Left ventricular afterload, effect of calcium antagonists on, 340
- Left ventricular dysfunction, nifedipine for, 345, 347
- Left ventricular work, in cardiac performance measurement, 291
- Legal liability, of medical consultant, in pregnancy, 557-565
- Lethargy, in dementia, treatment of, 1405
- Leukocytoclasia, in Sweet's syndrome, 1238
- Leukocytosis, in pyogenic liver abscess, 849
- Leukoderma, vitiligo-like, in subacute cutaneous lupus erythematosus, 1076
- Leukopenia, neonatal, azathioprine and, 677-678
- Levamisole, for chronic hepatitis B, 976
- Lichen planus, basement membrane zone band in, 1265
with systemic lupus erythematosus, 1107
- Lichen planus-like lesions, penicillamine-induced, 1288-1289
with gold therapy, 1286-1287
- Lichen sclerosus et atrophicus, with localized scleroderma, 1147
- Lifestyle techniques, in weight control program, 191
- Lipemia, postalimentary, high density lipoproteins and, 878
- Lipids, abnormalities of, drug selection considerations with, 467
and cardiovascular disease risk factors, 218
levels of, and risk of atherosclerotic coronary heart disease, in elderly, 1525-1530
in obesity, 149
mobilization from adipocytes, control of, 84
plasma, drug effect on, calculations of, 467
serum, effect of α_1 -blockers on, 464
effect of atenolol on, 458
effect of beta-blockers on, 459, 460
effect of labetalol on, 461
effect of metoprolol on, 456
effect of nonthiazide diuretics on, 454
effect of prazosin on, 463
effect of propranolol on, 455
effect of thiazides on, 452
- Lipoatrophy, in lupus erythematosus panniculitis, 1116
- Lipogenesis, from excess carbohydrates, 104
nibbling vs gorging in, 105
regulation of, 85
- Lipolysis, regulation of, 86
- Lipoprotein(s), and cardiovascular disease risk factors, 218
electrophoresis of, 875
high density, metabolism of, 865
protection from atherosclerosis by, 878
high density, lovastatin for, 444
low density, metabolism of, 864
metabolism of, 438-439
aging and, 1525-1526
body fat distribution and, 126
plasma, 859-860
classification of, 861
metabolism of, 860-865
production of, 860-863
properties of, 861
very low density, production of, 864
- Lipoprotein lipase, deficiency of, familial, 866-869
elevation of, in obesity, 85
in regional fat deposition, 88
- Lisinopril, adverse effects of, 331
clinical efficacy of, 326
for chronic congestive heart failure, hemodynamic effects of, 321
renal effects of, 324
- Lithium, teratogenic effects of, 576-577
- Lithotripsy, extracorporeal shock wave, 765-766
laser, 906
- Liver. See also under *Hepatic; Hepato-*
abscess of, 847-858
amebic, 851, 853-856
pyogenic, 847-853
alcoholic fibrosis of, 820
cancer of, liver transplantation for, 1017-1018
carcinoma of, 985-997. See also *Hepatocellular carcinoma*.
computed tomography of, 896
disease of. See *Liver disease*.
dysfunction of, in hemochromatosis, 836
failure of, 955-970. See also *Hepatic failure*.
fibrosis of, drug-induced, 782
in hemochromatosis, 833
focal lesions of, imaging of, 897-899
function of, in pregnancy, 1041
granulomas of, drug-induced, 783
imaging of, 895-909

- injury to, drug-induced, 782-783, 784
pathology of, in biliary cirrhosis, 914
transplantation of, 1011-1039. See also
Liver transplantation.
- Liver disease, alcoholic, 815-830
and hemochromatosis, 833
and hepatocellular carcinoma, 1001
biochemical abnormalities in, 821-824
clinical features of, 821-824
diagnosis of, 823-824
histopathology of, 817-821
liver enzyme abnormalities in, 822
liver transplantation for, 1016
pathogenesis of, 815-817
population at risk for, 821
prognosis in, 822-823
therapy for, 824-825
differential diagnosis of, 899
drug-induced, 775-792
acute, 776-777
chronic, 777-783
idiosyncratic, 784-785
mechanisms of, 783-786
spectrum of, 775-783
types of, drug categories in, 778-779
in pregnancy, 1041-1046
necroinflammatory, chronic, 777
primary, and hepatocellular carcinoma,
1001-1002
- Liver failure, fulminant, 955-970. See also
under *Hepatic failure.*
- Liver graft, dysfunction of, 1027-1029
rejection of, 1029-1031
- Liver transplantation, 1011-1039
contraindications to, 1012
disease recurrence in, 1033
donor selection for, 1020-1021
for hepatic encephalopathy, 807
for primary biliary cirrhosis, 922
immunosuppressive therapy in, 1023-
1027
indications for, 1012-1020
medical complications following, 1027-
1033
operative considerations in, 1021-1023
orthotopic, for fulminant hepatic failure,
965
patient selection for, 1011-1012
pediatric, 1020
pregnancy following, 681
timing of surgery for, 1011-1012
- Livido reticularis, in systemic lupus erythe-
matosus, 1101-1102
- Locus of control, in obesity, 52
- Loop diuretics, 273-274
for volume overload, 277
- Lovastatin, adverse effects of, 445-446
and liver disease, 788
chemistry of, 440
clinical experience with, 441-444
clinical use of, 445-446
combination therapy with, 443-444
for hypercholesterolemia, 437-448, 881
for hyperlipidemia, 1529
pharmacokinetics of, 440-441
pharmacology of, 440
structural formula of, 440
- Low air-loss beds, for pressure ulcer treat-
ment, 1518-1519
- Low calorie diets, for obesity, 203-215
- Low carbohydrate diets, for obesity, 205,
207
- Lower extremities, disability of, role in falls,
1330
- Lubricants, for constipation treatment,
1504-1505
- Lumbar puncture, in stroke evaluation, 1356
- Lumbar spine, stenosis of, in elderly, 1374-
1375
- Lung. See under *Pulmonary; Respiratory.*
- Lupus anticoagulant, patients with, features
of, 610
screening for, 615
suppression of, and improved pregnancy
outcome, 611
- Lupus band test, 1065-1066
for cutaneous lupus erythematosus,
chronic, 1264-1266
subacute, 1269
for rheumatoid arthritis, 1271
for scleroderma, 1270-1271
for systemic lupus erythematosus, 1267-
1270
for vasculitis, 1271
- Lupus dermatitis, photosensitive, in acute
cutaneous lupus erythematosus, 1095-
1096
- Lupus erythematosus, bullous, 1098
in acute cutaneous lupus erythemato-
sus, 1096-1097
cutaneous, acute, lesions specific for,
1094-1097
chronic, 1055-1071
hypertrophic, 1058-1059, 1061, 1064
immunofluorescence in, 1065-1066
lupus band test for, 1264-1266
mucosal, 1060
pathogenesis of, 1066-1067
pathology of, 1062-1065
treatment of, 1068
subacute, 1073-1090
annular, 1076
cutaneous features of, 1074-1078
definition of, 1074
disease associated with, 1087
drug-induced, 1087
epidemiology of, 1074
histopathology of, 1078-1079
immunogenetic associations with,
1083-1085

Lupus erythematosus (Continued)

- cutaneous, subacute, immunopathology of, 1078-1079
 - laboratory features of, 1081-1083
 - lesions specific for, 1097-1099
 - lupus band test for, 1269
 - manifestations of, 1073-1086
 - overlap with other rheumatic disorders, 1086
 - systemic features of, 1079-1081
 - treatment of, 1085-1086
- cutaneous immunofluorescence for, 1263
- definition of, 1055
- discoid, 1056-1058
 - basement membrane zone band in, 1265-1266
 - lesions specific for, 1057, 1099
- drug-induced, lupus band test for, 1270
- in elderly, 1377
- juvenile dermatomyositis vs, 1203
- neonatal, lupus band test for, 1270
- penicillamine-induced, 1289
- systemic, activity of, pregnancy and, 606-608
 - alopecia in, 1104
 - and stroke, 1355
 - basement membrane zone band in, 1268
 - bullous, lupus band test for, 1267-1268
 - chilblain lupus in, 1103-1104
 - cutaneous lesions in, 1091-1111
 - digital gangrene in, 1104
 - diseases associated with, 1107-1108
 - fertility in, 605-606
 - history of, 1091-1092
 - lesions specific for, 1094-1099
 - livido reticularis in, 1101-1102
 - lupus band test for, 1267-1269
 - maternal, management recommendations for, 614-616
 - outcome of pregnancy in, 608-609
 - pre-eclampsia vs, 616
 - reproductive performance in, 609
 - mucous membrane lesions in, 1106
 - nail changes in, 1107
 - nodular lesions in, 1104-1106
 - nonspecific cutaneous lesions in, 1100-1107
 - periungual erythema in, 1103
 - photosensitivity and, 1093-1094
 - Raynaud's phenomenon in, 1103
 - soft tissue calcification in, 1106
 - telangiectasias in, 1103
 - therapy for, cutaneous lesions secondary to, 1108
 - vascular lesions in, 1100-1101
 - vesiculobullous, 1096-1097
 - with leukocytoclastic vasculitis, 1228
 - with Sweet's syndrome, 1238
- Lupus erythematosus panniculitis, 1113-1126. See also *Panniculitis*.
- Lupus mastitis, in lupus erythematosus panniculitis, 1116
- Lupus nephritis, and maternal death, 607
- Lupus nephropathy, and fetal outcome, 609
- Lupus profundus. See *Panniculitis*.
- Lupus syndrome, neonatal, 613-614
- Lymphocyte count, measurement of, in elderly, 1540-1541
- Lymphoid inflammation, in lupus erythematosus panniculitis, 1117-1119
- Macrosomia, in infants of diabetic mothers, 686
- Magnesium hydroxide, cathartic dosage of, 1504
- Malabsorption, in weight control, 254
- Malaise, in pyogenic liver abscess, 849
- Malar rash, in acute cutaneous lupus erythematosus, 1094-1095
- Male, hormonal changes in, with advancing age, 1484-1485
- Malignancy, dermatomyositis and, 1211-1220
 - with Sweet's syndrome, 1238
- Malnutrition, protein-calorie, in elderly, 1542-1547
- Malpractice actions, prima facie case in, 557-562
- Mammogenesis, in lactation, 584
- Management plan, in medical record, 563
- Mastitis, breastfeeding in, 592
 - differential diagnosis of, 596
- Maternal drug therapy, fetal effects of, 591, 611-613
- Maternal-fetal genotype, interaction with environmental teratogen, 568
- Maternal morbidity, causes of, 519-527
 - effect on fetus, 546
 - in organ transplant recipients, 667-675
 - in pre-eclampsia, 624
- Maternal mortality, causes of, 519-527
 - definition of, 519
 - in organ transplant recipients, 667-668
 - with AIDS, 706
 - with cardiac disease in pregnancy, 641
 - with disseminated intravascular coagulation, 730
 - with systemic lupus erythematosus, 607
- Mattress type, in pressure ulcer prevention, 1516
- Meal, thermic response to, 100
- Mean arterial pressure, with angiotensin-converting enzyme inhibitors, 321
- Meclofenemate sodium, cutaneous reactions to, 1281-1282
- Medical care, standard of, breach of, in medical liability, 559-561

- Medical consultant, in pregnancy, legal liability of, 537-565
 role of, 541-555, 564-565
 recommendations of, compliance with, 542
 risk management by, 562-564
- Medical disease, breastfeeding and, 583-603
 effect of pregnancy on, 545-547
- Medical record, in malpractice litigation, 563
- Medication, in pregnancy, risks of, 548-549
- Medication compliance, in elderly, 1551-1563
 determinants of, 1554-1556
 promotion of, 1558-1561
- Medication regimen, compliance with, promotion of, 1558-1560
 noncompliance with, detection of, 1556-1558
 prevalence of, 1551-1554
- Mediterranean fever, familial, 1243
- Melanoma cell cultures, extraction of tissue-type plasminogen activator from, 389
- Memory, testing of, in acquired cognitive disorder, 1390
- Mental status examination, in acquired cognitive disorder, 1389
- Meritene, for hyperalimentation, 1546
- Mesenteric ischemia, in elderly, emergency operation for, 1418
- Metabolic acidosis, 279
- Metabolic alkalosis, diuretics for, 279
- Metabolic diseases, and hepatocellular carcinoma, 1002-1003
 liver transplantation for, 1016-1017
- Metabolic mass, and energy expenditure, 16
- Metabolic profile, relationship to body fat distribution, 121-126
- Metabolic rate, resting, determinants of, 227
 genetic effect on, 75
 in energy expenditure, 97
 in obesity, 105, 219
 postexercise, 223
- Methimazole, teratogenic effects of, 574
- Methotrexate, cutaneous reactions to, 1291
 for primary biliary cirrhosis, 922
 teratogenic effects of, 574
- Methyl cellulose, cathartic dosage of, 1504
- Methyl tert-butyl ether, for gallstones, 766-767
- Methylidopa, effect on serum lipids, 465
 for hypertension, in elderly, 1477
 in pregnancy, 672-674
 for Raynaud's phenomenon, 1136-1137
 in breast milk, 600
- Methylmercury, teratogenic effects of, 577
- Metoprolol, clinical trials of, 380, 416-418
 clinical use of, 419
 effect on serum lipids, 456
 for heart failure, 378
 in breast milk, 600
 nifedipine vs. for unstable angina, 426
- Metronidazole, for hepatic encephalopathy, 806
 in breast milk, 591
- Mezlocillin, for urinary tract infections, 1445
- Micronutrient requirements, in elderly, 1532-1533
- Mid-arm circumference, measurement of, in elderly, 1538-1539
- Milk, biosynthesis of, 586
- Milk-ejection reflex, 587
 inhibition of, alcohol and, 571
- Milrinone, chemical structure of, 304
 for congestive heart failure, 304
 hemodynamic effects of, 306
 pharmacokinetics of, 298
- Mineral oil, cathartic dosage of, 1504
- Mineral status, effect of aging on, 1540
- Mini-Mental Status Examination, of
 acquired cognitive disorder, 1389
- Mitral annulus, calcification of, and stroke, 1355
- Mitral insufficiency, in pregnancy, 643
- Mitral stenosis, in pregnancy, 642-643
- Mixed connective tissue disease, as variant of systemic sclerosis, 1178-1179
 lupus band test for, 1270
- Mobility, restricted, and urinary incontinence, 1427
 role in falls, 1329, 1332
- Moisture, and pressure ulcers, 1514
- Monoclonal antithymocyte globulin, for immunosuppression, in liver transplantation, 1026-1027
- Monoclonal gammopathy, with pyoderma gangrenosum, 1255
- Mood disorders, clinical description of, 1400
- Morbid obesity, definition of, 251
- Morphea, in localized scleroderma, 1143-1145
- Motor units, synchronization of, and tremor, 1307
- Movement tremor, in elderly, 1308
- Mucinosi, dermal, in systemic lupus erythematosus, 1106
- Mucocutaneous toxicity, penicillamine-induced, 1288
 to gold therapy, 1286
- Mucous membrane lesions, in systemic lupus erythematosus, 1106
- Multi-infarct dementia, clinical description of, 1396-1398
- Multiple gestations, single intrauterine fetal demise in, coagulopathy in, 733-734
- Multiple sclerosis, and urinary incontinence, 1424
 tremor with, 1316

- Muscle contraction, initiation of, 288
- Muscle disease, in dermatomyositis, 1182-1185
- in juvenile dermatomyositis, 1199-1200
- Muscle enzymes, in dermatomyositis, 1184
- in juvenile dermatomyositis, 1202
- Musculoskeletal system, inflammation in, in subacute cutaneous lupus erythematosus, 1079
- Myalgias, in systemic scleroderma, 1172
- Myeloma, with pyoderma gangrenosum, 1255
- Myocardial contractility, decreased, in pre-eclampsia, 626
- effect of calcium antagonists on, 341
- Myocardial failure, acute, neurohumoral responses in, 316
- Myocardial function, deterioration in, with nifedipine, 346
- Myocardial infarction, acute, and stroke, 1354
- calcium channel blockade for, 422-429
- diltiazem for, 427-429
- effect of cocaine on, 479-482
- nifedipine for, 423-426
- recombinant tissue-type plasminogen activator therapy for, 399
- thrombolytic therapy in, 387-407
- verapamil for, 423
- beta-adrenergic blockade in, 409-436
- calcium channel blockade in, 409-436
- cardiovascular mortality risk following, long-term reduction of, 411
- cocaine-induced, case summaries of, 480-483
- early phase of, beta-adrenoceptor blockade in, 416
- prevention of, beta-adrenergic blockade for, 410-411
- with coronary artery disease, and congestive heart failure, 293
- Myonecrosis, postpartum, 718
- Myosin, ATP-bound, in muscle contraction, 289
- in cardiac muscle tension, 286
- Myositis, in eosinophilic fasciitis, 1159
- Nadolol, in breast milk, 600
- Nailfold changes, in dermatomyositis, 1182, 1184, 1212
- in juvenile dermatomyositis, 1195-1196
- in systemic lupus erythematosus, 1106-1107
- Naloxone, for weight control, 243-244
- Naproxen, cutaneous reactions to, 1280-1281
- National Health and Nutrition Examination Survey, 4, 9
- Nausea, in pyogenic liver abscess, 849
- Necrotizing fasciitis, postpartum, 718
- Neglect, with cerebral infarction, 1362
- Negligence, malpractice actions for, prima facie case in, 557-562
- Neomycin, for hepatic encephalopathy, 806
- lovastatin with, 443-444
- Neonatal lupus syndrome, 613-614
- Neonatal morbidity, incidence by gestational age, 522
- predictors of, 523
- Neonatal mortality, definition of, 518
- incidence by gestational age, 522
- predictors of, 523
- Nephritis, lupus, and maternal deaths, 607
- Nephron physiology, diuretic pharmacology and, 272
- Nephropathy, diabetic, definition of, 688
- lupus, and fetal outcome, 609
- Nephrotic syndrome, lovastatin for, 444
- Neural tube defects, with maternal diabetes, 691
- Neuroectodermal tumors, childhood, maternal phenytoin therapy and, 572
- Neurogenic bladder dysfunction, long-term catheterization for, 1441-1442
- Neurologic claudication, in lumbar spinal stenosis, 1374
- Neurologic disorders, in Behçet's disease, 1241
- Neurologic examination, in acquired cognitive disorder, 1389
- Neurologic function, role in falling, 1326, 1332
- Neuropsychiatric complications, following liver transplantation, 1032-1033
- Neuropsychotropics, and liver disease, 778
- Neurotoxins, synergistic action of, in hepatic encephalopathy, 801
- Neurotransmitters, and nutrient balance control, 37
- false, in hepatic encephalopathy, 801-802
- Neutropenia, with captopril, 331
- Newborns, antibiotics contraindicated in, 592
- Nibbling, gorging vs, in lipogenesis, 105
- Nicardipine, for heart failure, 351-352
- Nicotinic acid, for hypercholesterolemia, 881
- Nifedipine, clinical experience with, 343-347
- digoxin with, 348-349
- effect on heart rate, 342-343
- for acute myocardial infarction, clinical studies of, 423-426
- results with, 430
- for heart failure, comparison with other agents, 347
- for hypertension in pregnancy, 672-674
- Nimety, in weight control, 252
- Nipples, infection of, in lactating diabetic, 597
- Nisoldipine, for heart failure, 352

- Nitrates, action of, mechanism of, 362-363
in congestive heart failure, 361-371
effects on mortality, 367-368
tolerance to, 365-367
- Nitrendipine, for heart failure, 352
- Nitrogen balance, negative, in very low calorie diets, 212
- Nitroglycerin, for acute hypertension in pregnancy, 632-633
nifedipine vs, 347
therapy with, tolerance to, 366
- Nitroprusside, for acute hypertension in pregnancy, 631-632
nifedipine vs, 348
- Nodular lesions, in lupus erythematosus panniculitis, 1114
in systemic lupus erythematosus, 1104-1106
- Nonsteroidal anti-inflammatory agents, chemical classification of, 1276
cutaneous reactions to, 1275-1283
fetal effects of, 612
- Norepinephrine, for congestive heart failure, 301
- Norton scale, of pressure ulcer risk, 1515
- Nortriptyline, cathartic dosage of, 1504
- Nutrients, balance of, afferent signals of, 34-36
and obesity, 29-45
control of, 30-34, 36-38
restriction of, in weight-loss diet, 207
utilization of, 32
- Nutrition, and aging, 1531-1549
and pressure ulcers, 1516, 1519
assessment of, in elderly, 1536-1542
deficiencies of, after gastric restriction surgery, 260
in hepatic encephalopathy, 806-807
in weight control program, 192
planning of, for wellness, 1532-1535
- Nutritional supplementation, for alcoholic liver disease, 825
- Obese personality, 49-52
- Obesity, 1-269
age at onset, 162-165
and exercise, 217-236
behavioral management of, 185-201
clinical evaluation of, 174-181
algorithm for, 178-181
concept of cure in, 237
definition of, 7-8, 161
development of, factors in, 173-174, 177
diagnosis and prevalence of, 1-13
diet and, 20-22, 171-172, 203-215
drug-induced, 172-173
drug treatment of, 237-249
eating style in, 54-56
economic factors in, 173-174
endocrine aspects of, 139-160, 170
energy dynamics in, 97-110, 170-171, 219-227
etiologic factors in, 165-174, 176-177
genetics in, 57, 67-81, 165-169
health risks of, 111-138
inconsistent findings in, 115-118
heterogeneous phenotype of, 67-68, 118-120
hypothalamic, 22-23, 172
in animals, 23
in familial hypertriglyceridemia, 872
morbidity, 251
multifactorial phenotype of, 68-69
nutrition in, 29-45, 100-103
prevalence of, 8-10
psychological factors in, 47-66, 173-174
relation to health, 111-115
risks of, 118, 178-181
social factors in, 173-174
surgical treatment of, 251-264
anatomic-physiologic principles in, 252-254
candidates for, 251
complications of, 259-261
methods of, 252-256
results of, 256-261
techniques in, 254-256
syndromes of, comparison of, 167
thinking style in, 52
types of, 68
- Ocular disorders, in Behçet's disease, 1241
- Old age, pharmacodynamic changes in, 489
pharmacokinetic changes in, 488-489
- Oliguria, following liver transplantation, 1033
- Opioid antagonists, for chronic constipation, 1506
for weight control, 243-244
- Optifast diet, for obesity, 209
- Oral supplements, for hyperalimentation, 1546
- Organ transplant recipients, pregnancy in, 667-683
- Organic mental syndromes, clinical descriptions of, 1394-1400
- Orthostatic hypotension, 1337-1349. See also under *Hypotension*.
- Osmolite HN, for hyperalimentation, 1545
- Osmotic agents, for constipation, 1504-1506
- Osteoarthritis, in elderly, 1372-1373
complications of, 1373-1375
- Osteochondrosis, intervertebral, in elderly, 1373-1374
- Osteomalacia, with osteoporosis, 1464
- Osteomyelitis, and pressure ulcers, 1520
- Osteoporosis, in elderly, 1455-1470
diagnosis of, 1457-1459
in men, 1459

- Osteoporosis (*Continued*)
 in elderly, medical conditions associated with, 1459
 risk factors for, 1456-1457
 treatment of, 1460-1467
 in primary biliary cirrhosis, 912
 Ovarian function, in obesity, 145-146, 170
 Ovarian veins, acute postpartum thrombosis of, 717
 Overeating, and obesity, 171
 chronic, adaptation to, 76-78
 definition of, 47
 response to, 100-103
 Overflow incontinence, 1429-1430. See also *Urinary incontinence*.
 Overlap syndrome, in dermatomyositis, 1185-1186
 Overweight, measurement of, 174-175
 Oxandrolone, for alcoholic liver disease, 824
 Oxicans, cutaneous reactions to, 1282-1283
 Oxygen, for acute asthma in pregnancy, 657
 hyperbaric, for pyoderma gangrenosum, 1257
 Oxygen supply, and cardiac contraction, 291
 Oxyphebutazone, cutaneous reactions to, 1282
 Oxyprenolol, for hypertension in pregnancy, 672-674
 Oxytocin, effect on milk ejection, 586-587
- Pain perception, in elderly, decrease in, 1414
 Pallor, in Raynaud's phenomenon, 1133
 Pancreas, cancer of, biliary stent for, 904
 endocrine, in obesity, 139-141
 hyposecretion of, with primary biliary cirrhosis, 913
 Pancreatitis, in elderly, acute abdomen with, 1416-1417
 in familial hyperlipoproteinemia, 873
 in fulminant hepatic failure, 962
 Panniculitis, lupus erythematosus, 1059-1062, 1113-1126
 clinical findings in, 1113-1117
 differential diagnosis of, 1121-1122
 diseases associated with, 1117
 electron microscopic findings in, 1123
 histopathologic findings in, 1117-1121
 immunopathologic findings in, 1122-1123
 in systemic lupus erythematosus, 1105
 incidence of, 1114
 laboratory findings in, 1123-1124
 pathology of, 1064-1065
 relationship to other connective tissue disease, 1121-1122
 treatment of, 1124-1125
- Papaverine injection, for erectile dysfunction, 1490
 Papulosquamous lesions, in subacute cutaneous lupus erythematosus, 1074
 Paramethadion, teratogenic effects of, 573
 Parathyroid function, in obesity, 148
 Parathyroid hormone, for osteoporosis, 1467
 Parenteral hyperalimentation, for protein-calorie malnutrition, 1544
 Parkinson's disease, and urinary incontinence, 1424
 dementia in, 1398
 tremor in, 1313-1315
 Patent ductus arteriosus, in pregnancy, 644
 Pathergy, in pyoderma gangrenosum, 1247
 Pathologic tremor, in elderly, 1310-1315
 Patient education, medication compliance promotion by, 1555, 1556-1559
 Peak expiratory flow rate, in acute asthma, 655
 Peliosis hepatis, drug-induced, 782-783
 Pelvic infection, persistent, postpartum, 715-716
 Pelvic thrombophlebitis, infection and, postpartum, 716-718
 Pemphigus, penicillamine-induced, 1289
 D-Penicillamine, cutaneous reactions to, 1288-1290
 Penis, lacerations of, with urinary tract catheterization, 1447
 prosthesis for, for erectile dysfunction, 1490
 Peptic ulcer, in elderly, acute abdomen with, 1416-1417
 Percutaneous transluminal coronary angioplasty, following thrombolysis, 401-402
 Perinatal morbidity, gestational age at, 520
 Perinatal mortality, causes of, 520-521, 523
 definition of, 518
 gestational age at, 520, 523
 in disseminated intravascular coagulation, 730
 Peritoneal dialysis, history of, risk of ectopic pregnancy with, 675
 Periurethral infections, with urinary tract catheterization, 1446
 Personality disturbance, and obesity, 49
 Pharmacogeriatric studies, complicating factors in, 491-492
 Pharmacotherapy, with behavioral program for obesity, 197
 Phenethylamine, for appetite suppression, 239
 Phenobarbital, in breast milk, 599
 Phenobarbitone, for essential tremor, 1312
 Phenothiazine use, role in falls, 1330
 Phenylbutazone, cutaneous reactions to, 1282
 Phenylpropanolamine, for weight control, 242-243

- Phenytoin, for weight control, 243
 in pregnancy, 664
 metabolism of, and liver disease, 785
 teratogenic effects of, 572
- Phlebotomy, for hemochromatosis, 839
- Phosphodiesterase inhibitors, for congestive heart failure, 303-307
- Phospholipid(s), in bile, synthesis of, 756
- Phospholipidosis, chronic, drug-induced, 777
- Photosensitivity, in subacute cutaneous lupus erythematosus, 1078, 1097
 in systemic lupus erythematosus, 1092-1094
- Physical activity, energy expenditure from, 106, 227-228
 for weight loss maintenance, 198
 low level of, and obesity, 170-171
- Physical therapy, fall prevention by, 1333-1334
 for juvenile dermatomyositis, 1205
- Physician-patient relationship, and medical compliance, 1555
- Physiologic tremor, in elderly, 1309-1310
- Physiology, altered, in pregnancy, 542-544
- Pigment stones, in gallbladder, formation of, 758
- Pigmentation, abnormalities of, in systemic scleroderma, 1170
 with antimalarials, 1285
 in hemochromatosis, 836
- Pindolol, for heart failure, 378
 evidence against, 380
- Piperacillin, for urinary tract infections, 1445
- Piroxicam, cutaneous reactions to, 1282-1283
- Pituitary disorders, in obesity, 141-148, 170
- Pityriasiform lesions, in subacute cutaneous lupus erythematosus, 1075
 with gold therapy, 1287
- Placebo drug trials, ethical considerations in, 505-506
 problems with, 500
- Placenta, drug transport across, 569
- Placental abruption, and disseminated intravascular coagulation, 730-732
- Placental hormones, in fetal diagnosis, 535-536
- Plasma lipids, drug effect on, calculations of, 467
 transport of, and coronary heart disease risk, 877-879
- Plasma volume, in pregnancy, 639
 effect on seizure disorders, 661
- Plasmin, function of, in coagulation, 726
- Pneumonia, aspiration, with dermatomyositis, 1188
- Poikiloderma, in dermatomyositis, 1182, 1184, 1212
- Polyarteritis nodosa, 1224, 1230
- Polyarthritis, symmetrical, inflammatory, in elderly, 1376-1377
- Polycythemia, in infants of diabetic mothers, 687
- Polymorphonuclear infiltrates, in cutaneous vasculitis, 1226-1227
- Polymorphous light eruption, lupus dermatitis vs, 1095
- Polymyalgia rheumatica, inflammatory symmetrical polyarthritis vs, 1376-1377
- Polymyositis, with dermatomyositis, 1185
- Porphyria, and secondary hemochromatosis, 839
 basement membrane zone band in, 1265
 with systemic lupus erythematosus, 1108
- Portal blood flow, measurement of, 935-937, 940-941
- Portal hypertension, 931-953. See also under *Hypertension*.
- Portal-systemic collateral circulation, 932
 in hepatic encephalopathy, 796-797
- Postural hypotension. See *Hypotension*, *orthostatic*.
- Postural sway, in elderly, effect on falling, 1324
- Postural tremor, in elderly, 1308
 in Parkinson's disease, 1313
- Potassium, depletion of, diuretics and, 276
- Prader-Willi syndrome, and obesity, 168
- Prazosin, effect on serum lipids, 463
- Preadipocytes, regulation of, 91
- Prednisolone, for chronic hepatitis B, 973
- Prednisone, fetal exposure to, 677
 for alcoholic liver disease, 824
 for asthma in pregnancy, 658
 for eosinophilic fasciitis, 1163
 for juvenile dermatomyositis, 1204-1205
- Pre-eclampsia, and disseminated intravascular coagulation, 736
 and liver dysfunction, 1044
 chronic hypertension vs, 624
 definition of, 623
 differential diagnosis of, 671
 hemodynamic monitoring in, 625, 627
 in renal transplant patients, 672-674
 maternal morbidity in, 624
 systemic lupus erythematosus vs, 616
 therapy for, 627
- Pregnancy, acute coagulopathy in, 723-743
 and disseminated intravascular coagulation, 727-737
 and kidney transplant rejection, 669
 anticonvulsant medication in, 662-663
 as dynamic state, 549-551
 asthma in, 653-660
 autoimmune disease in, 605-621
 cardiac disease in, 639-651
 cardiovascular alterations of, 639-640
 dermatomyositis in, 1190-1191

Pregnancy (*Continued*)

- diabetes in, 685-700
 - management of, first trimester, 689-691
 - second trimester, 691-692
 - third trimester, 692-695
- diagnostic procedures in, 544-545
 - interpretation of, 547-548
- factors unique to, 542-551
- human immunodeficiency virus infection in, 701-711
- hypertensive crisis in, 623-638
- in renal transplant recipients, 667-683
- infections in, 713-721
- insulin action in, 686
- liver disease in, 1041-1046
 - cirrhosis, 1044-1045
 - fatty liver, 1043-1044
 - intrahepatic cholestasis, 1043
 - pre-eclampsia/eclampsia, 1044
 - viral hepatitis, 1041-1043
- lupus activity in, 606-610
- medical disease in, 545-547
- medical problems in, 517-752
- medications in, risks of, 548-549
- physiology in, 550, 685-686
 - alterations in, 542-544
- respiratory changes in, 653-654
- role of medical consultant in, 541-555
- seizure disorders in, 661-665
- serum alkaline phosphatase activity during, 545
- surgery in, risks of, 549
- termination of, 517
- tests for, reliability of, 523
- Prekallikrein, levels in pregnancy, 727
- Premature labor, risk of, in renal transplant patients, 680
 - tocolytic therapy for, 524
- Prematurity, morbidity with, 521-522
 - risk factors for, 528-529
 - with maternal renal transplant, 676
- Prenatal injury, evidence for, 526
- Prescription medications, noncompliance with, detection of, 1557
 - prevalence of, 1551-1554
- Pressure ulcers, in elderly, 1511-1524
 - assessment of, 1516-1517
 - classification of, 1511
 - complications of, 1514-1515
 - infection with, 1514
 - local care of, 1520-1522
 - pathogenesis of, 1513-1514
 - pathophysiology of, 1512-1514
 - prevalence of, 1512
 - prevention of, 1515-1516
 - risk factors for, 1512-1514
 - treatment of, 1516-1522
- Presyncope, in stroke, 1353
- Primidone, for essential tremor, 1312
 - in breast milk, 599
- Problem-oriented medical record, in medical consultation, 563
- Probuco, for hypercholesterolemia, 881
- Progesterone, in pregnancy, effect on seizure disorders, 661
- Progressive systemic sclerosis, with dermatomyositis, 1185
- Prolactin, in obesity, 143
 - role in milk production, 585-587
- Propionic acids, cutaneous reactions to, 1280-1281
- Propranolol, clearance rate of, 490, 492
 - clinical use of, 419
 - effect on serum lipids, 455
 - for esophageal varices, 946
 - for essential tremor, 1312
 - for heart failure, 378
 - evidence against, 380
 - in breast milk, 600
 - in elderly, 489-491
 - intravenous, clearance of, age and, 492
 - kinetics of, age and sex in, 491
 - systemic availability of, 490
- Propylthiouracil, for alcoholic liver disease, 824
 - teratogenic effects of, 574
- Prostacyclins, for hepatic encephalopathy, 807
- Prostate cancer, in obesity, 115
- Prosthetic heart valve, and stroke, 1354
- Protein, requirements for, in elderly, 1532-1533, 1535, 1541-1542
- Protein C, function of, in coagulation, 726
- Protein-calorie malnutrition, in elderly, 1542-1547
- Proteinuria, in cutaneous vasculitis, 1225
 - in renal transplant patients, in pregnancy, 674
 - with captopril, 331
- Prothrombin ratio, in liver failure, 943
- Proximal tubule, diuretic action in, 271-273
- Pruritus, in primary biliary cirrhosis, 911
- Pseudoporphyria, naproxen-induced, 481
- Psoriasis, with corticosteroid withdrawal, 1284
 - with systemic lupus erythematosus, 1075, 1108
 - worsening of, with antimalarials, 1285
- Psychiatric complications, following liver transplantation, 1032-1033
- Psychiatric intervention, for chronic constipation, 1507
- Psychological factors, in medical compliance, 1553, 1559
 - in obesity, 47-66
- Psychosocial examination, in acquired cognitive disorder, 1388, 1391
- Psyllium, cathartic dosage of, 1504
- Puerperal infection, pathophysiology of, 713-716

- Puerperium, anticonvulsant medication in, 662-663
- Pulmocare, for hyperalimentation, 1545
- Pulmonary circulation, in pregnancy, 640
- Pulmonary disease, with dermatomyositis, 1186-1188
with systemic scleroderma, 1172
- Pulmonary edema, in pre-eclampsia, 627
nifedipine for, 344
- Pulmonary emboli, with postpartum pelvic thrombophlebitis, 717
- Pulmonary hypertension, in pregnancy, 645-646
- Pulmonary maturity, fetal, in maternal diabetes, 693-694
- Pulmonary vasculature, effect of nitrates on, 363
- Pulse therapy, for pyoderma gangrenosum, 1257-1258
- Pulsus paradoxus, in acute asthma, 654, 655
- Purpura, in cutaneous vasculitis, 1224-1225
- Pyelonephritis, with urinary tract catheterization, 1447-1448
- Pyoderma gangrenosum, 1243-1244, 1247-1261
atypical, 1250
clinical features of, 1248-1250
conditions associated with, 1252-1255
definition of, 1247
differential diagnosis of, 1255-1256
etiology of, 1251-1252
evaluation of, 1255-1256
histopathology of, 1250
pathogenesis of, 1251-1252
treatment of, 1256-1258
- Pyostomatitis vegetans, in pyoderma gangrenosum, 1249-1250
- Pyrazolones, cutaneous reactions to, 1281
- Quality of life, in obesity, effect of surgery on, 258-259
- Quinacrine, cutaneous reactions to, 1284-1285
- Quinidine, and digitalis toxicity, 299
- Radiation, fetal effects of, 534, 547
- Rash, in juvenile dermatomyositis, 1195
- Raynaud's disease, 1127-1128
- Raynaud's phenomenon, and disease, 1127-1141
clinical evaluation of, 1133-1134
conditions associated with, 1130-1133
definition of, 1127-1128
epidemiology of, 1129-1130
in systemic lupus erythematosus, 1102
in systemic scleroderma, 1167, 1170, 1174
laboratory evaluation of, 1134
pathophysiology of, 1128-1129
prevention of, 1135-1136
sympatholytics for, 1136-1137
therapy for, 1134-1139
- Rebound tenderness, in acute abdomen, 1414
- Recanalization, with thrombolytic therapy, 396
- Recombinant tissue-type plasminogen activator, administration of, 390-391
clinical development of, 388-389
efficacy of, 391-394
for acute myocardial infarction, 387-407
mortality with, 400, 401
patency rates with, 393
patient selection for, 389-390
pharmacology of, 387-388
safety of, 394-397
side effects of, 396-397
- Reinforcement, in weight control program, 193
- Relationship techniques, in weight control program, 192
- Reliability, of tests, definition of, 537
- Renal. *See* *Kidney*.
- Renin-angiotensin-aldosterone system, 317-319
- Repositioning, in pressure ulcer prevention, 1515-1516
- Reserpine, in breast milk, 600
- Respiratory insufficiency, in obesity, effect of surgery on, 258
with dermatomyositis, 1188
- Respiratory muscles, accessory, use of, in acute asthma, 655
- Respiratory physiology, in pregnancy, changes in, 550, 653-654
- Respiratory rate, in acute asthma, 655
- Rest tremor, in elderly, 1308
in Parkinson's disease, 1313
- Retained dead fetus syndrome, and disseminated intravascular coagulation, 732-733
- Reticuloendothelial system, defects in, and hemochromatosis, 835
- Retinoids, cutaneous reactions to, 1293-1294
- Reye's syndrome, microvesicular steatosis in, 958
- Rheumatic syndromes, in elderly, treatment of, 1371-1381
- Rheumatoid arthritis, inflammatory symmetrical polyarthritis vs, 1376-1377
juvenile, juvenile dermatomyositis vs, 1203
lupus band test for, 1271
with cutaneous lupus erythematosus, 1086
with dermatomyositis, 1185
with leukocytoclastic vasculitis, 1228
with Sweet's syndrome, 1238

- Rheumatoid-like nodules, in systemic lupus erythematosus, 1105
- Rheumatologic disorders, drugs for, cutaneous reactions to, 1275-1298
- Ribavirin, for chronic hepatitis B, 976
- Right-to-left shunts, in pregnancy, 644-648
- Risk management, in medical consultation, 562-564
- Ro-antibody, in subacute cutaneous lupus erythematosus, 1099
- Rubral tremor, 1316
- Salicylates, cutaneous reactions to, 1277-1278
- Salsalate, cutaneous reactions to, 1278
- Salt intake, increase in, for orthostatic hypotension, 13
- restriction of, for hypertension, 1474
- Sample population, for drug trials, selection of, 504
- Sarcomere, length of, 284-285
- Satiety, in weight control, 252
- Schistosomiasis, and hepatocellular carcinoma, 1000-1001
- Schizophrenia, medication noncompliance in, 1553
- Sclerodema, as variant of systemic scleroderma, 1177-1178
- Scleroderma, and Raynaud's phenomenon, 1130-1132
- linear, 1145
- localized, 1143-1156
- associated findings in, 1147
- clinical features of, 1143-1147
- differential diagnosis of, 1151-1153
- "en coup de sabre" lesion in, 1145-1146
- epidemiology of, 1148-1149
- histology of, 1148
- laboratory abnormalities in, 1149-1150
- onset findings in, 1147
- overlap with systemic disease, 1150-1151
- pathogenesis of, 1148
- prognosis in, 1151
- subcutaneous involvement in, 1147
- treatment of, 1153-1154
- variants of, 1143-1147
- lupus band test for, 1270-1271
- spectrum of, 1168
- systemic, 1167-1180
- antibodies to, 1173
- classification of, 1167-1172
- cutaneous features of, 1167-1172
- laboratory findings in, 1172-1173
- pathogenesis of, 1173-1174
- prognosis in, 1176-1177
- systemic features of, 1171-1172
- therapy for, 1174-1176
- variants of, 1177-1179
- Scleromyxedema, as variant of systemic scleroderma, 1177-1179
- Sclerotherapy, for esophageal varices, 945-947
- Screening, for weight control program, 194
- Sedimentation rate, elevated, in cutaneous vasculitis, 1226
- in leukocytoclastic vasculitis, 1231
- in pyogenic liver abscess, 849
- Seizure, stroke vs, 1355
- Seizure disorders, in pregnancy, 661-665
- Self-monitoring, in behavioral programs for obesity, 190
- Senile gait, definition of, 1326
- Senile tremor, in elderly, 1310-1311
- Senna extract, cathartic dosage of, 1504
- Sepsis, and coagulopathy, 734-735
- in elderly, findings in, 1419
- Serotonin neurotransmitters, anorexiant drugs acting on, 241-242
- Serum alkaline phosphatase activity, during pregnancy, 545
- Serum lipids. See *Lipids, serum*.
- Serum sickness, as hypersensitivity vasculitis, 1223, 1229
- Set-point, body weight, energy expenditure and, 19-19
- Sex hormones, in regional fat deposition, 88
- Sexual function, with advancing age, 1483-1495
- Sharp's syndrome, as variant of systemic scleroderma, 1178-1179
- Shearing forces, and pressure ulcers, 1514
- Sheepskin, for pressure ulcer treatment, 1517
- Shoulder, arthritis in, in elderly, 1376
- Shy-Drager syndrome, orthostatic hypotension vs, 1342
- Sickness Impact Profile, in obesity, 259
- Silicone catheters, for urinary tract catheterization, 1442
- Sjögren's syndrome, inflammatory symmetrical polyarthritis vs, 1376-1377
- with cutaneous lupus erythematosus, 1086
- with dermatomyositis, 1185
- with leukocytoclastic vasculitis, 1228
- with Sweet's syndrome, 1238
- with systemic lupus erythematosus, 1107
- Skeletal hyperostosis, diffuse idiopathic, in elderly, 1375
- Skin, breakdown of, with incontinence, long-term catheterization for, 1441-1442
- infections of, with corticosteroid withdrawal, 1284
- protection of, in juvenile dermatomyositis, 1206
- Skinfold measurements, and health risks, 119

- for body fat determination, 4-7
- genetic effect on, 72
- in elderly, 1538-1539
- Smoking, and impotence, 1487
 - cessation of, for hypertension in elderly, 1474
 - effect on resting metabolic rate, 106
- Social support, in weight control program, 193
- Sodium ion exchange, increase in, inotropic action on, 296
- Sodium nitroprusside, for acute hypertension in pregnancy, 631-632
- Sodium-potassium-chloride step, of loop diuretics, effects of blocking, 273-274
- Soft tissue calcification, in systemic lupus erythematosus, 1106
- Somatomedin, in obesity, 142
- Somatostatin, for esophageal varices, 945
- Sorbitol, for chronic constipation, 1504, 1506
- Spermatogenesis, decreased, with aging, 1484
- Spherocytosis, hereditary, and secondary hemochromatosis, 838
- Sphincterotomy, endoscopic, of bile duct, 768, 903
- Spina bifida, with maternal diabetes, 691
- Spinal cord lesions, and urinary incontinence, 1424
- Spine, degenerative changes of, in elderly, complications of, 1373-1375
- Spirometry, in acute asthma, 655
- Standing, blood pressure response to, 1338-1340
- Stature, calculation of, in elderly, 1538
- Status epilepticus, in pregnancy, 662
- Steatonecrosis, alcoholic, 817-819
- Steatorrhea, in primary biliary cirrhosis, 912
- Steatosis, alcoholic, 817-818
 - drug-induced, 777
 - microvesicular, in Reye's syndrome, 958
- Sterilization, in AIDS patient, 706
- Steroids. See also *Corticosteroids*.
 - anabolic, and hepatocellular carcinoma, 1004
 - for osteoporosis, 1467
 - for maternal systemic lupus erythematosus, 616
 - for septic shock, 735
- Stillbirth, definition of, 518
- Stimulus control, in behavioral programs for obesity, 190
- Stool impaction, and urinary incontinence, 1427
- Stool softeners, for constipation treatment, 1504-1505
- Streptokinase, recombinant tissue-type plasminogen activator vs, 394-395
- Streptomycin, teratogenic effects of, 577
- Stress, and orthostatic hypotension, 1340
- Stress incontinence, 1424, 1429-1430. See also *Urinary incontinence*.
 - and sexual problems, in aging females, 1491
- Stroke, in elderly, 1351-1369
 - diagnosis of, 1356-1358
 - differential, 1352-1356
 - features of, 1358-1359
 - recurrence of, 1363
 - treatment of, decisions in, 1358-1360
 - programs for, 1360-1366
- Suckling, milk stimulation by, 588
- Sucrose polyester, for weight control, 247
- Sulfinac, cutaneous reactions to, 1278-1279
- Sulfonamides, for pyoderma gangrenosum, 1257
- Sulfones, for pyoderma gangrenosum, 1257
- Sunscreen, for cutaneous lupus erythematosus, 1068
- Suppositories, for chronic constipation, 1506
- Suprapubic catheters, for urinary incontinence, 1451
- Suprofen, cutaneous reactions to, 1281
- Surgery, for obesity, 251-264
 - with behavioral program, 197
 - for pressure ulcers, 1521-1522
 - in pregnancy, risks of, 549
- Sway, in elderly, effect on falling, 1324
- Sweet's syndrome, findings in, 1237-1239
- Sympathetic nervous system, effect of cocaine on, 476-478
- role in thermic effect of food, 101
- Sympatholytic agents, for hypertension, in elderly, 1477
 - in pregnancy, 628-630
 - for Raynaud's phenomenon, 1136-1137
- Sympathomimetic amines, adrenergic receptor activity of, 302
- Synchrony, in muscle contraction, 286-287
- Syncope, in stroke, 1353
- Systemic lupus erythematosus. See under *Lupus erythematosus*.
- Systemic sclerosis, localized scleroderma vs, 1151-1152
- Systolic dysfunction, in congestive heart failure, 292
- T cells, circulating levels of, in primary biliary cirrhosis, 917
- Tachycardia, catecholamine-mediated, beta-blocker therapy for, 375-376
 - in juvenile dermatomyositis, 1200
- Taste disturbance, with captopril, 331
- Telangiectasia, in juvenile dermatomyositis, management of, 1206
 - in systemic lupus erythematosus, 1103
 - in systemic scleroderma, 1167-1169, 1171

- Temporal arteritis, and stroke, 1355
Teratogen, definition of, 567
Teratogenesis, mechanisms of, 569
Teratology, principles and practice of, 567-582
Terbutaline, for asthma in pregnancy, 658
Testicular dysfunction, in obesity, 143-145
Testicular size, decreased, with aging, 1484
Testosterone, and sexual function, in aging females, 1492
 decrease in, with aging, 1484
 for erectile dysfunction, 1489
 levels of, in obesity, 143-144
 side effects of, 1490
Tetracycline, teratogenic effects of, 577-578
Tetralogy of Fallot, in pregnancy, 644-645
Thalamotomy, for essential tremor, 1311
Thalassemia, and secondary hemochromatosis, 838
Thalidomide, teratogenic effects of, 578
Theophylline, for acute asthma in pregnancy, 656
Thermogenesis, facultative, in energy expenditure, 99
 postprandial, 223
Thermogenic drugs, for weight control, 244-245
Thiazides, effect on serum lipids, 452
 for idiopathic hypercalciuria, 278
 for osteoporosis, 1467
Thinking style, in obesity, 52
Thorotrast, and hepatocellular carcinoma, 1005-1006
Thrombin, increased activity of, in pregnancy, 724
Thrombocytopenia, neonatal, azathioprine and, 677-678
Thromboembolism, in elderly, treatment of, 1360-1365
Thrombolytic therapy, administration protocol for, 390-391
 contraindications to, 390
 for acute myocardial infarction, 387-407
 patient selection for, 389-390
 reperfusion with, 397-400
 safety of, 394-397
 treatment after, 400
Thrombophlebitis, pelvic, postpartum infection and, 716-718
Thyroid disease, breastfeeding in, 597-598
Thyroid function, in obesity, 147-148
Thyroid hormone, for weight control, 244
Thyroxine, role in lactation, 586
Tidal volume, in pregnancy, 654
Time/bowel retraining, in constipation treatment, 1503
Timolol, clinical use of, 419
 in breast milk, 601
Tissue-culture solutions, for pressure ulcer treatment, 1521
Tissue iron, quantitation of, 834
Tissue-type plasminogen activator. See *Recombinant tissue-type plasminogen activator*.
Tobac, for body fat determination, 3
Tocolytic agents, for premature labor, 524
Tolmetin, cutaneous reactions to, 1279
Toxemia, seizure disorder vs, 662
Toxic epidermal necrolysis, bullae with, 1279
Toxic megacolon, with chronic constipation, 1507
Toxic shock syndrome, breastfeeding in, 592
Toxin theory, of Alzheimer's disease, 1385-1386
Toxins, and hepatocellular carcinoma, 1003-1006
 synergistic action of, in hepatic encephalopathy, 801
Transfer factor, for chronic hepatitis B, 977
Transferrin, laboratory standards for, 1541
 measurement of, in elderly, 1539
 receptors of, in hemochromatosis, 835
Transforming growth factor-alpha, in hepatocellular carcinoma, 992-993
Transient ischemic attack, carotid endarterectomy for, 1364
 in elderly, diagnostic evaluation of, 1356-1358
 signs of, 1353
Trauma, and lupus erythematosus panniculitis, 1116
Trauma theory, of Alzheimer's disease, 1386
Travasorb, for hyperalimentation, 1545
Trazadone, cathartic dosage of, 1504
Tremors, in elderly, 1307-1319
 classification of, 1308-1310
 definition of, 1307-1308
 drug-induced, 1310-1311, 1316
 frequency of, 1309
 functional, 1317
 in Parkinson's disease, 1313-1315
 post-traumatic, 1317
Trichinosis, juvenile dermatomyositis vs, 1203
Tricyclic antidepressants, cathartic dosage of, 1504
Triglycerides, increased hepatic synthesis of, thiazide-induced, 450
 lovastatin for, 444
 regulation of, 84
Trimethadione, in pregnancy, 663
 teratogenic effects of, 573
Trimethaphan, for acute hypertension in pregnancy, 630
Trimethoprim-sulfamethoxazole, for urinary tract infections, 1445
Troponin C-Ca²⁺ responsiveness, increase in, inotropic action on, 296-297
Tuberculosis, breast-feeding in, 592

- Tubular physiology, review of, 271
- Tumor, and urinary incontinence, 1424
- stroke vs, 1355
- Tyrosinemia, and hepatocellular carcinoma, 1002
- Ulcerations, in pyoderma gangrenosum, 1248
- Ulcerative colitis, in primary sclerosing cholangitis, 1014
- with pyoderma gangrenosum, 1249, 1253
- with Sweet's syndrome, 1238
- Ultrasonography, endoscopic, 906
- for gallstones, 759-760
- in fetal diagnosis, 532-533
- in second trimester, in diabetes, 691-692
- Ultraviolet light, and chronic cutaneous lupus erythematosus, 1067
- and systemic lupus erythematosus, 1093
- Undernutrition, response to, 100-103
- Underwater weighing, for body fat determination, 2
- Urethra, function of, changes with aging, 1426
- incompetence of, in urinary incontinence, 1424-1426
- injuries to, with urinary tract catheterization, 1447
- Urge incontinence, 1428-1430. See also *Urinary incontinence*.
- Urinary. See also *Bladder*.
- Urinary flow rate, in urinary incontinence, 1425
- Urinary incontinence, in dementia, treatment of, 1405
- in elderly, 1423-1439
- established causes of, 1428-1430
- evaluation of, 1430-1435
- functional, 1425
- indwelling catheters for, 1441
- medical causes of, 1426-1428
- medications contributing to, 1428
- pathophysiology of, 1424-1425
- prevalence of, 1423-1424
- treatment of, 1433
- prevention of, in pressure ulcer prevention, 1516
- Urinary stones, with urinary tract catheterization, 1448
- Urinary tract catheterization, catheter care in, 1450
- catheter choice for, 1442-1443
- closed drainage system for, 1443-1444
- complications of, local, 1443-1447
- systemic, 1447-1449
- indications for, 1441-1442
- intermittent, for urinary incontinence, 1436, 1450-1451
- long-term, alternatives to, 1450-1451
- in elderly, 1441-1454
- Urodynamics, bedside, interpretation of, 1432, 1434
- in urinary incontinence, 1425-1426
- Urosepsis, with urinary tract catheterization, 1448
- Ursodeoxycholate, for gallstones, 763-764
- Ursodeoxycholic acid, for primary biliary cirrhosis, 921-922
- Urticaria, in systemic lupus erythematosus, 1101
- Uterine infection, risk factors for, 713
- Uterine pain, with abruptio placentae, 731
- Uteroplacental insufficiency, and perinatal complications, 522
- Vacuum tumescent device, for erectile dysfunction, 1489
- Vaginal bleeding, with abruptio placentae, 731
- Vagotomy, for weight control, 256
- Validity, of tests, definition of, 537
- Valproate, metabolism of, and liver disease, 785
- Valproic acid, in breast milk, 599
- in pregnancy, 664
- teratogenic effects of, 573
- Varicella-zoster infection, breastfeeding in, 594
- Vascular disease, and impotence, 1486-1487
- Vascular lesions, in systemic lupus erythematosus, 1100-1101
- Vascular resistance, systemic, in pregnancy, 639-640
- Vasculitis, and stroke, 1355
- classification of, 1222
- cutaneous, 1221-1235
- clinical features of, 1224-1226
- definition of, 1221
- laboratory findings in, 1226
- pathology of, 1226-1228
- systemic involvement in, 1225
- in elderly, 1377-1378
- leukocytoclastic, diseases associated with, 1228-1231
- evaluation of, 1231-1233
- history in, 1232
- laboratory examinations in, 1231
- microscopic findings in, 1237
- subgroups of, 1228-1231
- treatment of, 1232
- lupus band test for, 1271
- lymphocytic, in lupus erythematosus panniculitis, 1119
- pathogenesis of, 1222-1224
- pustular, 1239
- Vasoactive agents, for systemic scleroderma, 1175

- Vasoconstriction, catecholamine-induced, beta-blocker therapy for, 375
- Vasodilators, effect on serum lipids, 465-466 for acute hypertension in pregnancy, 630-634 for pre-eclampsia, 627 for Raynaud's phenomenon, 1137-1138 nifedipine vs, 347-348
- Vasopressin, diuresis with, 280-281 effect on hepatic venous pressure, 941 for esophageal varices, 944 in obesity, 148 levels of, effect on renin-angiotensin-aldosterone system, 319
- Vasospasm, in Raynaud's phenomenon, 1129
- Vegetarian diets, for obesity, 204
- Venesection, therapeutic, for hemochromatosis, 839
- Veno-occlusive disease, drug-induced, 782
- Veno-venous bypass system, for liver transplantation, 1022
- Venous pooling, and orthostatic hypotension, 1341
- Ventricular filling pressure, effect of nitrates on, 362-363
- Ventricular function, following thrombolytic therapy reperfusion, 397-400
- Ventricular preload, effect of calcium antagonists on, 341-342
- Ventricular septal defect, in pregnancy, 644
- Verapamil, and digitalis toxicity, 299 effect on heart rate, 342 for acute myocardial infarction, clinical studies of, 423 results with, 430 nifedipine vs, 349-350
- Vertebral fractures, in elderly, 1375
- Vertebral joints, arthritis involving, in elderly, 1373
- Very low calorie diets, for obesity, 203-215
- Vesicoureteral reflux, with urinary tract catheterization, 1449
- Vidarabine, for chronic hepatitis B, 975
- Vinyl chloride, and hepatocellular carcinoma, 1005-1006
- Viral hepatitis, 971-983. See also *Hepatitis*.
- Viral infection, and Behçet's disease, 1240 and dermatomyositis with malignancy, 1216 and juvenile dermatomyositis, 1194 fetal exposure to, 679
- Visuospatial tasks, testing of, in acquired cognitive disorder, 1390
- Vitamin(s), requirements for, in elderly, 1532-1533
- Vitamin D, for osteoporosis, 1464-1465
- Vitiligo, in juvenile dermatomyositis, 1196, 1198
- Vitiligo-like leukoderma, in subacute cutaneous lupus erythematosus, 1076
- Vivonex T.E.N., for hyperalimentation, 1545
- Volume overload, diuretics in, 276-277
- Vomiting, in pyogenic liver abscess, 849 with gastric restriction surgery, 259
- Von Willebrand's disease, coagulopathy in, 737
- Waist-to-hip ratio, and health risks, 120 and metabolic profile, 121 for body fat determination, 5
- Walking program, effect on body weight, 231
- Wandering, in dementia, treatment of, 1404
- Warfarin, embryopathy with, 571 for stroke prophylaxis, 1363
- Weakness, in juvenile dermatomyositis, 1199
- Wegener's granulomatosis, in elderly, 1378 with cutaneous leukocytoclastic vasculitis, 1229
- Weight, calculation of, in elderly, 1537-1538 change in, after gastric restriction surgery, 260 whole body metabolic response to, 24 in body fat determination, 3 monitoring of, in protein-calorie malnutrition, 1543
- Weight-height index, 4
- Weight loss, diets for, 203-215 for hypertension in elderly, 1474 maintenance of, strategies for, 197-199 programs for, 191-192 surgical approach to, 251-264
- Weight training, effect on body composition, 233
- Wellness, nutritional planning for, 1532-1535
- Wheezing, in acute asthma, 655
- Wilson's disease, liver transplantation for, 1017
- Wound infection, postpartum, life-threatening, 718-719
- Wound irrigation, for pressure ulcer treatment, 1521
- X-linked obesity, 169
- Xanthomas, eruptive, in familial type V hyperlipoproteinemia, 873
- Zinc, deficiency in, and impotence, 1488
- Zinc sulfate, for pressure ulcer treatment, 1519

